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Immune checkpoint inhibitors (ICIs) have drastically improved the clinical outcome for many 
cancer patients. However, not all patients treated with ICIs show a clinical response and the 
development of a unique spectrum of adverse events, termed immune-related adverse events 
(irAEs), restricts their oncological applicability. Additionally, the production of anti-drug antibodies 
(ADAs) may negatively influence patient outcome, but their role during therapy is yet to be 
established due to limitations in standard detection techniques. The primary aim of this exploratory 
study was to identify biomarkers that predict patient outcome to prevent a proportion of individuals 
exposed to a potentially ineffective and/or harmful therapy. It was hypothesized that patients who 
develop anti-drug antibodies experience a decrease in treatment efficacy and/or an increase in 
toxicity. Furthermore, patients with differing outcomes in terms of response, survival and the 
development of toxicity may display distinct clinicopathological characteristics. 
 
A retrospective review was performed on 32 patients undergoing nivolumab or pembrolizumab 
monotherapy for metastatic melanoma. Blood serum trough samples from 8 pembrolizumab-treated 
patients were analysed using in-house developed ELISA’s to measure pembrolizumab and anti-
pembrolizumab antibody levels. Of the patients reviewed, 23 (72%) were ineligible for inclusion in 
initial clinical trials of ICI drugs. 29 patients (91%) experienced irAEs and 13 (41%) progressed 
during treatment. No clinicopathological variables were found to significantly predict patient 
outcome. Anti-pembrolizumab antibodies were detected in one patient and correlated with 
decreased blood serum drug levels. In this patient case, the individual responded to treatment 
according to RECIST, but, developed irAEs (pneumonitis and infusion reactions). 
 
This study indicates that, patients who are ineligible for initial clinical trials may effectively be 
treated with immune checkpoint inhibitors. Further investigation in a larger cohort is required to 
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Immunotherapy is rapidly cementing its position as the fourth pillar of cancer treatment.1 In contrast 
to the three traditional cancer treatments (surgery, radiation and chemotherapy) which target cancer 
cells, the mechanistic target of immunotherapy is the patient’s natural immune cells.2 One of the 
first examples of immunotherapy dates back to 1891, when Dr. William Coley successfully treated 
sarcoma patients by injecting bacterial toxins to evoke an immune response.3,4 However, multiple 
deaths and the concurrent arrival of radiation and chemotherapy halted the momentum of 
immunotherapy.5 Nonetheless, continued efforts investigating a number of immunotherapeutic 
approaches ensued over the following century. The result, a myriad of potential immunotherapeutic 
treatments ranging from cytokines and small molecules to vaccines and engineered immune cells, 
many of which have yielded modest results and limited clinical applicability.6,7,8 That is, until the 
recent success of a novel class of immunotherapeutic agents known as immune checkpoint 
inhibitors (ICIs). The development and introduction of ICIs has drastically improved the clinical 
outcome for many cancer patients, particularly melanoma patients.5,9,10,11,12  
New Zealand has the highest rate of melanoma in the world and skin cancers (melanoma 
plus non-melanoma cancers) are the most common cancers in New Zealand, accounting for 80% of 
all new cancer diagnoses each year. Although melanoma diagnoses occur less frequently than non-
melanoma skin cancer diagnoses, they represent a bleaker outcome for patients, making up 70% of 
all skin cancer deaths.149 The approval and transition of ICIs into clinical practice is expected to 
improve survival rates of New Zealanders diagnosed with melanoma.150 However, not all patients 
treated with ICIs show clinical response, and ICIs generate a unique spectrum of side effects that 
differ from that of traditional cancer treatments.10,11 These effects, termed immune related adverse 
events (irAEs), resemble autoimmune disease and target various tissues (e.g skin, gastrointestinal 
tract, endocrine organs) to produce a multitude of manifestations (e.g rash, colitis, endocrine 
dysfunction).13,14,15,16,17 Moreover, irAEs can be debilitating and lead to the discontinuation of 
therapy, irreversible organ damage and/or death.11,18 Interestingly, however, the appearance of 
irAEs has been associated with an improved clinical outcome to ICI-therapy.100,103,104,105  
The first approved checkpoint inhibitor, ipilimumab, targets cytotoxic T-lymphocyte antigen 
4 (CTLA-4), producing durable responses in patients with advanced melanoma. Disadvantageously, 
however, approximately one third of patients treated with Ipilimumab experience severe or life-
threatening effects, referred to as grade 3 or 4 events, respectively.2,10 Inhibition of an alternative 
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immune checkpoint, programmed death 1 (PD-1), has produced a more favourable benefit-to-risk 
ratio, leading to the FDA-approval of two anti-PD-1 antibodies, Nivolumab and 
Pembrolizumab.11,19,20,21 However, as with all therapeutic antibodies, unwanted immunogenicity 
and more precisely, the production of anti-drug antibodies (ADAs) towards ICIs may alter this 
benefit-to-risk ratio, limiting their success.147   
 The overall goal of this project was to improve our understanding of patient immune 
response to ICIs and optimise their clinical use. The first aim of this study was to investigate 
clinicopathological indicators of patient outcome through the retrospective review of patients 
undergoing anti-PD-1 therapy. The second aim was to use an in-house developed ELISA to 
measure drug and anti-drug antibody levels in patients undergoing ICI-therapy and, correlate the 
resulting laboratory data with clinicopathological characteristics collected for each patient 
(including age, gender and patient outcome). Thirdly, we aimed to identify serum markers that 
could be used to predict patient outcome, particularly with regards to the development of irAEs. 
Currently there are no known biomarkers predictive of toxicity in patients treated with PD-1 
inhibitors. By identifying predictive biomarkers of toxicity, the underlying mechanisms and 
therefore causes of irAEs may be determined. Moreover, such biomarkers would allow early 
detection and improved management of these reactions, as well as the avoidance of unnecessary 
toxicity and healthcare costs. Therefore, to prevent a proportion of patients exposed to an 
ineffective and potentially harmful therapy, this project focuses on identifying biomarkers of patient 
outcome. Of particular interest, were biomarkers of patient response, survival and development of 
toxicity in patients with metastatic melanoma treated with nivolumab or pembrolizumab.  
 
1.1! Cancer and the immune system 
Although initially controversial, the major role of the immune system in tumour surveillance is now 
widely recognised. ‘Cancer immunoediting’, a leading concept describing the immune system’s 
influence on tumour progression, proposes three distinct phases of immune surveillance: 
elimination, equilibrium and escape.22,23,24 Each phase represents a dynamic interaction in which 
multiple effector cells and secreted cytokines play a pivotal role.23,25 During the elimination phase, 
transformed tumour cells are successfully destroyed by the host’s immune system. If unsuccessful, 
the equilibrium phase can proceed. The host’s immune system is unable to fully eliminate the 
tumour cells but can adequately restrain their growth, leading to a period of dormancy. 
Accompanied by appropriate genetic changes these tumour cells can evade the immune system, 
thereby escaping immunosurveillance. Tumour cells enter the escape phase where they begin to 
proliferate, progressively forming a clinically detectable tumour.23,24 Hanahan and Weinburg 
introduced the ‘Hallmarks of Cancer’ to describe traits that normal cells acquire during their 
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transformation into cancerous cells and progression into this escape phase. Included in these traits is 
the ability of a cancer cell to evade immunosurveillance.26 Multiple ways in which cancer cells 
achieve this have been theorized.27 One established mechanism involves the up-regulation of 
immune checkpoint molecules on cancer cells that promote suppression of the hosts immune 
system.28,29 Understanding these mechanisms has allowed the development of therapeutic 
approaches such as immune checkpoint inhibitors that promote return to the equilibrium or 
elimination phase, thereby restraining or destroying tumour growth.   
 
1.2! Immune checkpoints 
Under normal physiological conditions, immune checkpoint molecules regulate T cell activation to 
generate an effective immune response, without inducing excessive inflammation or 
autoimmunity.30 According to the two-signal model of T cell activation, interactions between co-
signaling molecules on the surface of T cells and antigen-presenting cells (APCs) are required for 
optimal activation of a naive T cell.31,32 Furthermore, this interaction is believed to determine the 
amplitude of the T cell response. It is now understood that co-signaling molecules can act through 
co-stimulatory pathways promoting T cell activation, or oppositely, through co-inhibitory pathways 
that inhibit T cell responses.33 Evidence for an inhibitory role of immune checkpoint molecules to 
maintain immune homeostasis has come from a series of in vitro and in vivo experiments. In the 
case of two clinically relevant immune checkpoints, CTLA-4 and PD-1, in vitro experiments have 
demonstrated blocking with antibodies augments T cell responses, suggesting this blockade 
prevents transmission of an inhibitory signal.34,35 Additionally, blockade in mouse models of 
autoimmunity exacerbates autoimmune manifestations supporting a role of these molecules in self-
tolerance.36,37 CTLA-4 knockout mice develop a lymphoproliferative disorder which leads to fatal 
multi-organ tissue destruction and early death.38,39 Similarly, mice deficient in PD-1 display 
multiple autoimmune-like conditions including lupus-like arthritis, glomerulonephritis and 
encephalomyelitis.40,41,42,43 Interesting, however, it appears mice do not display patterns of toxicity 
similar to those of patients undergoing ICI-therapy. Common irAEs observed in ICI-treated patients 
are rarely seen in CTLA-4 or PD-1 deficient mice, which may explain why initial preclinical animal 
studies failed to predict these irAEs.134 Other compelling data has linked defects or functional 
mutations in CTLA-4 or PD-1 molecules with various autoimmune and inflammatory 
conditions.44,45 It is yet to be discovered whether these mutations play a role in the development of 
toxicity in patients undergoing immune checkpoint inhibitor therapy.  
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1.2.1! CTLA-4 and PD-1/PD-L1 pathway  
The most extensively studied immune checkpoint pathways, the CTLA-4 and PD-1 pathways, have 
proven to be clinically relevant in cancer therapy.10,11 Both CTLA-4 and PD-1 belong to the B7 
receptor family and are expressed on the surface of T cells.30 Differentially, however, CTLA-4 and 
PD-1 interact with different targets inducing distinct signaling pathways.46,47 CTLA-4, a CD28 
homolog, competitively binds B7 on APCs with high affinity.48 Following initial signaling and 
activation of a T cell through its T cell receptor, CTLA-4 is up-regulated. Binding of B7 to CTLA-4 
rather than CD28 prevents transference of the second co-stimulatory signal required for full 
activation of T cells. The proportion of CD28:B7 binding and CD28:CTLA-4 binding ultimately 
determines whether a T cell will become fully activated or undergo anergy. Therefore, an 
appropriate immune response can be generated without over-activation and autoimmunity or 
inflammation resulting. Blockade of CTLA-4 prevents binding to B7, shifting the proportion of 
binding to CD28:B7.47 This blockade allows greater activation of T cells, and consequently a more 
intense immune response to be generated. Conversely, PD-1 has been shown to bind either PD-L1 
(B7-H1, CD274) or PD-L2 (B7-DC, CD273).49,50 Within an unhindered immune system, the 
intended ligand of PD-1 is PD-L1 or PD-L2 expressed on the host’s immune cells.51 Similar to the 
CTLA-4 pathway, this interaction has been shown to restrict T cell activation preventing over-
activation and maintaining self-tolerance.47 However, a series of experiments have confirmed PD-1 
can alternatively bind PD-L1 or PD-L2 expressed on tumour cells.52,53,54,55 Furthermore, evidence 
suggests expression of PD-L1 or PD-L2 is a mechanism by which cancer cells exploit the PD-1 
immune checkpoint pathway to evade the immune system. Through binding and inhibition of PD-1 
by PD-L1 or PD-L2 expression, cancer cells are able to generate an immunosuppressive effect. As a 
result, cancer cells are able to evade the immune system, allowing persistence and progression 
within the host.56,57  
 Due to the differences described above, it is thought that immune checkpoint molecules 
function at different stages of the immune response. In contrast to CTLA-4, which is thought to 
regulate T cells at an early initial activation stage, PD-1 is believed to regulate the immune response 
at multiple stages, particularly at a later stage regulating effector T cells in peripheral tissues.47 
Figure 1.1 depicts the stages of the cancer-immunity cycle at which therapeutic agents, including 
CTLA-4 and PD-1 inhibitors are believed to exert their effects. The different stage at which CTLA-
4 inhibitors act compared to PD-1/PD-L1 inhibitors is believed to contribute to differences in drug 




Figure 1.1: Stages at which therapies might affect the cancer-immunity cycle. Anti-CTLA4 and 
anti-PD-1/PD-L1 antibodies are proposed to affect the cancer-immunity cycle at stage 3 and 7, 
respectively. Adapted from Chen and Mellman (2013).58 
 
1.3! Immune checkpoint inhibitors 
The recognition that immune checkpoint molecules can be blocked by antibodies to reverse immune 
suppression and therefore generate anti-tumour effects has prompted their emergence as therapeutic 
targets in cancer treatment.59,60 Early research has elucidated the chemical structures, signaling 
pathways and interactions of multiple immune checkpoint molecules within the immune system and 
tumour microenvironment.61,62,63 As a result, six immune checkpoint inhibitors have been 
developed and FDA-approved for the treatment of several cancer types.5,64,65 The two best 
characterised checkpoint pathways, the CTLA-4 and PD-1/PD-L1 pathway, are the main targets of 
clinically available inhibitory antibodies, as shown in Table 1.1, which summarises FDA-approved 
immune checkpoint inhibitors.5 Although, in an area of active research, promising data is emerging 
showing currently approved antibodies and newly developed antibodies targeting alternative 
checkpoints can exert anti-tumour effects in other tumour types.66,67,68,69,70  For example, data has 
shown Nivolumab exhibits promising activity in hepatocellular carcinoma and acute myeloid 
leukemia.66,67 Additionally, Lirilumab, a monoclonal antibody that targets KIR immune 
checkpoints, has demonstrated activity in head and neck cancer.69 
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Table 1.1: FDA-approved immune checkpoint inhibitors. Adapted from Sweis and Luke (2017), 
with information provided by the U.S Food & Drug Administration.5,64,65 
Target Drug Approval year Indication 
CTLA-4 Ipilimumab 2011 
2015 
Melanoma (metastatic/unresectable) 

















Non-small cell lung cancer  
Head and neck cancer 
 
Melanoma (metastatic/unresectable) 
Non-small cell lung cancer 
Renal cell carcinoma 
Hodgkin Lymphoma 
















Urothelial cancer, Lung cancer 
Non-small cell lung cancer 
 





1.3.1! Monotherapy  
Ipilimumab (Yervoy®, Bristol Myers-Squibb), the first and currently only approved checkpoint 
inhibitor targeting CTLA-4, is a humanized immunoglobulin G1 monoclonal antibody.71 Clinical 
trials in various tumour types have demonstrated Ipilimumab is effective in melanoma patients, but 
fails to produce clinical efficacy in other cancers.10,72,73,74 In contrast, successively approved 
inhibitors, Nivolumab (Opdivo®, Bristol Myers-Squibb) and Pembrolizumab (Keytruda®, Merck) 
are humanised IgG4 monoclonal antibodies, highly selective for human PD-1.75,76 Unfortunately, 
although a number of patients experience favourable outcomes, many patients don’t respond to 
treatment with ICIs.10,11 For example, in a phase III trial involving ipilimumab-treated melanoma 
patients, only 1.5% of patients achieved a complete response and a further 9.5% achieved a partial 
response. Disadvantageously, 59.3% of patients experienced progressive disease.10 Therefore, a 
huge demand exists for markers that will include (or exclude) patients from treatment based on their 
likelihood to respond to treatment or risk of developing toxicity.  
 
1.3.2! Combination therapy 
Considering CTLA-4 and PD-1 act through distinct signaling pathways, it was theorised that 
inhibition of both CTLA-4 and PD-1 could produce enhanced anti-tumour responses.47 For that 
reason, multiple trials examining the effectiveness of combination therapies involving ICIs are in 
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progress. Additionally, it is unknown whether the application of ICIs with traditional cancer 
treatments may provide a benefit to patients. Thus, these trials are not only investigating ICIs in 
combination with one another, but also with conventional cancer treatments including 
chemotherapy and radiation.77 Following a randomised, double-blind, phase III study, the first 
combination treatment of Ipilimumab plus Nivolumab was FDA-approved for the treatment of 
advanced melanoma in 2015. In patients with advanced melanoma treated with either Nivolumab 
alone or in combination with Ipilimumab, a greater response rate was found in the combination 
treatment group. Unfavourably, however, the incidence of grade 3-4 irAEs was significantly higher 
in the combination treatment group compared to monotherapy with either agent.78 To date, all irAEs 
observed with combination therapy have been observed in monotherapy suggesting homogeneous 
underlying mechanisms.  
 
1.4! Therapeutic antibodies  
The clinical applicability of antibodies spans far wider than their use as anti-cancer agents.  
Preceding their development as immunotherapeutic checkpoint inhibitors, antibodies have been 
engineered to treat a wide range of indications.136,141,144 Favourable properties including long serum 
half-lives and the ability to bind diverse targets with high specificity and affinity have garnered 
attraction for drug development.136 To date, all monoclonal antibodies approved for clinical use are 
of the IgG isotype of immunoglobulins (Figure 1.2).136,137 This classification is based on their 
similar basic structure, in which each antibody consists of four polypeptide chains (two heavy 
chains and two light chains) held together by disulfide bonds to form a large heterodimeric protein 
(~150kDa). Each light chain consists of a variable domain (VL) and a constant domain (CL). 
Similarly, each heavy chain consists of a variable domain (VH) but also three constant domains 
(CH1, CH2 and CH3). The Fab (fragment antigen binding) fragment, which allows the antibody to 
bind to the antigen, contains the complete light chains, as well as the VH and CH1 heavy chain 
domains. The remaining CH2 and CH3 domains form the Fc fragment (fragment crystallizable), 
which engages with cell surface receptors.137 As mentioned previously, nivolumab (146 kDa) and 
pembrolizumab (149 kDa) are further classified into the IgG4 subclass based on differences in 
sequence, structure and effector functions from the three alternative subclasses; IgG1, IgG2 and 
IgG3.75,76,137 Additional modifications to their structure, made possible through advances in 
antibody engineering, have permitted the humanization of these antibodies. Generation of 
therapeutic antibodies is routinely achieved from xenogenic sources and therefore, their structure 
contains sequences that may elicit an immune response in humans. Humanization is a well-
established technique that modifies non-human sequences to increase their similarity to naturally-
occurring human antibodies, ultimately reducing unwanted immunogenicity of mAbs when 
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administered to humans.136 Through the incorporation of suitable manipulations with basic 
structural properties, immune checkpoint inhibitors function as effective therapeutic agents.  
 
Figure 1.2: Generalized structure of an immunoglobulin (IgG). Reprinted from ThermoFisher 
Scientific. 138 
 
1.4.1! Anti-drug antibodies 
Nivolumab and pembrolizumab were engineered as humanized monoclonal antibodies (mAbs), to 
reduce the risk of developing anti-drug antibodies (ADAs).75,76,137 However, particularly with 
repeated infusions, administration of mAbs to patients may trigger undesirable immunogenicity, 
leading to ADA formation.136, 137 The subsequent binding of ADAs to mAbs has been linked to a 
decrease in drug efficacy and/or an increase in toxicity events for a wide range of therapeutic 
antibodies.140, 142, 144, 152  
In a study conducted by Vultaggio et al., an association between the formation of antibodies 
towards infliximab, a therapeutic antibody used to treat autoimmune diseases, and an increased risk 
of hypersensitivity reactions was reported.140 A number of further studies have reported a loss of 
efficacy in the presence of ADAs, including a study involving the first approved fully humanized 
mAb, adalimumab. In this study, anti-adalimumab antibodies were detected in 17% of patients and 
of these patients, 80% were non-responders.145 The change in response observed in these studies is 
proposed to originate from the formation of ADA-mAb immune complexes. Immune complexes 
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reduce efficacy of treatment by increasing clearance and reducing the bioavailability of the 
therapeutic antibody. Additionally, immune complexes can promote toxicity through various 
mechanisms including activation of the complement cascade, Fc receptors, and various 
inflammatory pathways.158 Figure 1.3 summarizes the central role of immune complexes within the 
immune system and capacity to exacerbate an ADA response. Furthermore, a subset of ADAs 
referred to as neutralizing antibodies, bind to epitopes situated directly within or near the active site 
of the therapeutic antibody altering the interaction with its target.137 With regards to anti-PD-1 
inhibition, the binding of nivolumab or pembrolizumb to PD-1 may be compromised, diminishing 
their blocking effect and ultimately their therapeutic effect.  
To maximize the anti-tumour effect of ICIs, an optimum concentration of drug must be 
available to the patient. Patients who generate ADAs towards ICIs may be at an increased risk of 
non-responding to treatment or developing adverse effects. In patients undergoing ICI-therapy, it is 
yet to be determined whether anti-drug antibodies induce these altered responses and, if so, to what 
extent. Monitoring of therapeutic antibodies and their respective anti-drug antibodies has become 
common practice for inflammatory bowel disease and arthritis patients (adalimumab and 
infliximab-treated patients), and is used to guide treatment regimens.151 However, testing of these 
parameters is not routinely performed for patients receiving immune checkpoint inhibitors. 
Accurate monitoring of both serum ICI levels and ADA levels will determine at-risk patients, 
improving usage of immune checkpoint inhibitors in a clinical setting. 
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Figure 1.3: The central role of immune complexes formed by therapeutic monoclonal 
antibodies in the interplay between innate and adaptive arms of the immune system and 
exacerbation of ADA response. ADA specific to complementary determining regions of a 
monoclonal therapeutic antibody is used as an example for ease of representing complex formation 
of varying sizes where n represents the number of cross-linked ADA Fc in immune complexes; in 
reality ADAs are polyclonal with varying specificities. Adapted from Krishna and Nadler (2016).158 
 
1.4.2! Methods of Anti-Drug Antibody Detection  
Multiple methods have been developed for the detection of therapeutic antibodies and anti-drug 
antibodies (ADAs). However, as of yet, there is no consensus on the optimal method of detection 
and measurement of these antibodies due to differences in sensitivity and specificity between 
techniques.146 Despite this, there is agreement that these parameters should be measured at ‘trough 
level’. Trough samples are taken prior to the patients next administered dose and thus, represent the 
lowest serum drug concentration. In contrast to peak levels, trough levels provide a better 
characterization of patient response by allowing time for the therapeutic antibody to undergo 
pharmacokinetic and pharmacodynamic processes.153 
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  To date, serum concentrations of therapeutic antibodies and their respective ADAs are 
predominantly measured using an enzyme-linked immunosorbent assay (ELISA).143 Typically, a 
bridging ELISA (bELISA) is used to detect ADAs due to superior specificity over conventional 
ELISA techniques.144 Bridging ELISAs rely on the binding of free ADAs to solid-phase therapeutic 
drug which in turn, can be identified using a labelled therapeutic antibody (Figure 1.4). 
Advantageously, ELISAs are quick, simple and cost-effective, permitting greater clinical 
applicability compared to alternative methods such as homogeneous shift mobility assays 
(HSMAs), which require specialist personnel and expensive equipment.146 However, HSMAs 
display high sensitivity, a feat that remains a major limitation of ELISA-based methods. During 
HSMAs, size exclusion high pressure liquid chromatography (SE-HPLC) is employed to 
distinguish free drug and ADA-drug complexes based on molecular weight differences.146 
Conversely, because ELISAs rely on the binding of free ADAs to solid-phase drug, they are unable 
to detect ADAs complexed to mAbs.143 To overcome this, Bourdage et al., described an affinity 
capture elution (ACE) ELISA-based assay for the detection of anti-drug antibody in the presence of 
drug. In contrast to previous ELISA methods, the ACE ELISA assay requires initial acid treatment 
of samples to dissociate ADA-mAb complexes and therefore, diminishes cross-interference from 
therapeutic antibody. Previously bound ADAs may then be detected through affinity-capture to 
solid-phase drug, similar to traditional ELISAs (Figure 1.5).141    
Currently, there are no commercial assays available for the detection of anti-ICI antibodies 
and little data has been published regarding their prevalence and influence on patient response. The 
limited data available has been conducted as part of the regulatory application for these drugs, and 
was performed using a standard bridging ELISA, which as mentioned above bears a number of 
limitations.148 Therefore, further immunogenicity investigations are required, especially in real life 
patients.147 Developing and validating an affinity capture elution (ACE) assay for detection of 
ADAs will help us determine the extent to which ADAs occur and alter patient response, ultimately 
improving our understanding of ICI immunogenicity and optimizing patient care. Additionally, a 
comparison with a standard bridging ELISA method will provide an insight into the accuracy of 






Figure 1.4: Key steps of the bridging ELISA to detect ADAs. ADAs from patient serum bind to 
therapeutic antibody (drug) coated on an ELISA plate. These ADAs are subsequently detected with 
therapeutic antibody labelled with biotin. Biotinylation allows for detection of the therapeutic 




Figure 1.5: Key steps of the affinity capture elute (ACE) ELISA to detect anti-drug 
antibodies. Firstly, acidification of patient serum dissociates ADA-drug complexes into free drug 
and free ADA. Following neutralization, ADAs are affinity captured in the in the presence of solid-
phase drug. After the removal of free drug by washing, acid-eluted ADA is transferred onto a fresh 
ELISA plate. Captured ADAs can then be detected through the addition of labelled therapeutic 
antibody attached to an enzyme and substrate. 
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1.5! Immune related adverse events (irAEs) 
Currently, there are limited guidelines on how to accurately interpret or record irAEs. Common 
terminology criteria for adverse events (CTCAE) grades events from 1-5 according to severity. Low 
grade events, grade 1 and 2, represent mild and moderate events, respectively. Whereas, high grade 
events, grade 3 and 4, describe severe events that are not immediately life-threatening (grade 3) or 
life-threatening (grade 4). Additionally, grade 5 indicates death related to an adverse event.79 
Systematic reviews have uncovered irAEs are inconsistently and inadequately reported in clinical 
trials. Notably, consistency in recording incidence, onset and duration of irAEs is lacking.80,81 
Similarly, a review by Michot et al. argued data such as time of onset, reversibility, management, as 
well as the recording of infrequent or unexpected events not initially thought to be immune related, 
should be accurately reported. Also highlighted was an absence of consistent terminology 
throughout the literature, with irAEs referred to as ‘drug-related adverse events’ or ‘events of 
special interest’.2 It appears that these inaccuracies may be partly attributed to the difficulty 
distinguishing between irAEs, non-immune events or typical autoimmune diseases.33 Paradoxically, 
inducing an anti-tumour response in patients induces similar responses to those that drive 
autoimmunity.82 Therefore, irAEs were initially thought to be similar to the autoimmune diseases 
that they symptomatically replicate.83 Now, however, it is believed the two are distinct from one 
another. For instance, women are more likely to present with autoimmune disease, however, no 
gender bias has been observed with irAEs.84 Moreover, age has proven to be a factor in various 
autoimmune diseases yet the question remains as to whether age has a role in the appearance of 
irAEs in ICI therapy.85 Additionally, correlations between identifying factors such as 
autoantibodies, antigen-specific T cells and MHC haplotypes have not been thoroughly analysed.82 
At present, factors that contribute to the onset of autoimmune-like irAEs seen with immune 
checkpoint inhibitor therapy remain unclear.  
 
1.5.1! Toxicity profiles 
An understanding of ICI toxicity is advancing following widespread treatment of patients outside of 
clinical trials. Toxicity can potentially present in any tissue forming an expansive clinical spectrum 
of irAEs as shown in Figure 1.6.2 Skin toxicities remain the most frequently reported irAE, with 
grade 1/2 events mainly occurring dermatologically.86,87 Conversely, grade 3/4 events are more 
prevalent within the GI tract, and approximately 20% of these events are estimated to be life-
threatening. 2,88  
In early clinical trials, CTLA-4 inhibitors and PD-1 inhibitors have been shown to exhibit 
distinct clinical profiles with regard to both efficacy and toxicity.10,11 Presumably, these differences 
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are due to their distinct inhibitory interactions.47 For example, as seen in Figure 1.7B, a higher 
incidence of hypothyroidism is associated with PD-1 inhibitors, whereas colitis is more likely to 
present in anti-CTLA-4 treated patients.89 PD-1 inhibitors appear to have a generally milder toxicity 
profile in comparison with CTLA-4 inhibitors. Studies indicate up to 90% of patients undergoing 
anti-CTLA-4 therapy and 70% of patients undergoing anti-PD-1 therapy experience irAEs.10,11 A 
recent meta-analysis reported a higher odds ratio for treatment-related deaths in patients treated 
with CTLA-4 inhibitors (OR=1.80) compared to patients treated with PD-1/PD-L1 inhibitors 
(OR=0.63).18 Despite the risk of serious complications and death, toxicities are usually 
appropriately managed and reversible, especially if recognised early, and particularly in anti-PD-1 
inhibitor therapy where irAEs are predominantly grade 1 or 2 in severity.2,87  
 Notably, variation in toxicity profiles has been observed within checkpoint inhibitor classes 
in different cancer types. In patients undergoing ICI therapy, it was initially thought vitiligo only 
presented itself in patients with melanoma.90 Vitiligo, an autoimmune disorder characterised by 
depigmentation of the skin has a long recorded relationship with melanoma.91 The link is thought to 
be mediated through an immune response towards antigens shared by normal melanocytes and 
melanoma cells.92 Unexpectantly, however, two recent case studies reported the first appearances of 
vitiligo in patients with lung adenocarcinoma and acute myeloid leukaemia following Nivolumab 
treatment.93,94 Regardless of an increased use of ICIs in melanoma patients, current literature 
inclusive of recent case studies indicates vitiligo is more apparent in melanoma patients compared 














Figure 1.6: Clinical spectrum of irAEs of immune checkpoint inhibitors. T1D, Type 1 




















Figure 1.7: Incidence of common (A) and rare (B) immune related adverse events in patients 
treated with ipilimumab, pembrolizumab, nivolumab or ipilimumab plus nivolumab. 
Reprinted from Boutros et al. 2016.89 
 
1.5.2! Pathophysiology of irAEs 
Despite a general understanding of immune checkpoint inhibition, the exact mechanisms underlying 
their anti-tumour effects remain unclear. Furthermore, little is known about the mechanisms 
mediating irAEs. Evidence has shown that some patients do not develop irAEs despite continuous 
use of ICIs, whilst others experience multiple irAEs throughout treatment.2,10,11 Additionally, 
patients may experience toxicity with one type of checkpoint inhibitor but not another.96,97,98 This 
may be assumed to be a result of differences in inhibitory targets, but the question remains as to 
why subtle differences in both efficacy and toxicity are emerging between Nivolumab and 
Pembrolizumab, two PD-1 inhibitors.89,99  
 
1.5.3! Appearance of irAEs and impact on ICI drug efficacy  
The literature is mixed with regards to the impact of irAEs of immunotherapy. An association 
between the development of irAEs and efficacy of ICI therapy has been reported but remains 




grade 3/4 irAEs and cancer regression in ipilimumab-treated patients. 36% of patients presenting 
with a grade 3/4 irAE achieved a response compared to 5% of patients who did not experience any 
irAEs.100 With logical reason it has been suggested that the appearance of irAEs is evidence of 
greater immune system stimulation caused by the immunotherapy. Multiple cutaneous irAEs, 
including vitiligo and hypopigmentation, are known positive prognostic factors in patients with 
melanoma.101,102 Hence, as immunotherapies may induce these irAEs, argument that a greater 
response occurs in patients presenting with these events is reasonable. A prospective observational 
study and a small number of retrospective analyses have reported an association between the 
appearance of cutaneous irAEs and response to anti-PD-1 therapy.103,104,105 These findings are 
consistent with previous studies on alternate immunotherapeutic approaches, which noted a 
correlation between the development of irAEs with improved survival in melanoma patients 
undergoing interleukin 2 and interferon alfa-2 immunotherapy.101,106  
 In contrast to studies described above, multiple studies have found no evidence of 
association between the development of toxicity and response to treatment with ICI-
therapy.107,108,109 The reported association of irAEs with anti-tumour responses may be due to lead 
time bias. Patients who respond to the immunotherapy undergo a longer treatment period and have 
more time to develop irAEs. Alternatively, those who do not respond or experience disease 
progression have a shorter treatment period due to a change to an alternative therapy or death.110 It 
is important to note that the onset of irAEs is not a prerequisite for response and all of the above 
studies also found anti-tumour responses in patients who did not experience irAEs. Despite this, the 
possible association between the appearance of irAEs and improved patient outcome observed in 
multiple studies should not be dismissed. 
 
1.5.4! Management of irAEs and impact on efficacy 
The FDA-approved Risk and Management System guides clinical management of irAEs induced 
from immune checkpoint inhibitor therapy. Algorithms generally suggest supportive measures for 
low grade irAEs, whereas temporary or permanent discontinuation of the drug is recommended for 
high grade irAEs.111 Additionally, administration of systemic corticosteroids and 
immunosuppressants may be advised in high grade events.2,111 Logically, it has been suggested that 
the dose and treatment regime must be closely managed to avoid a decrease in efficacy of the 
immunotherapy. Yet, current literature indicates adjunctive treatment with immunosuppressants 
does not influence the response to either CTLA-4 inhibitors or PD-1 inhibitors.100,109 Studies into 
the use of ICIs in organ transplant patients may help determine the impact of immunosuppressants 




Numerous studies have investigated biomarkers that may predict response to therapy. However, 
little focus has been extended to biomarkers which could predict the development of toxicity. 
Furthermore, no studies have been published that investigate biomarkers of toxicity in patients 
treated with PD-1/PD-L1 inhibitors. 
 
1.6.1! Biomarkers predictive of response to treatment 
In order to select patients most likely to benefit from treatment, previous literature has focused on 
identifying biomarkers that predict efficacy of ICI treatment. A focal point involves the 
intratumoural expression of PD-L1, and a number of studies have reported its association with 
enhanced clinical efficacy.11,112,113,114,115 An initial study conducted on nivolumab-treated patients 
found 9 out of 25 patients (36%) with PD-L1 positive tumour cells had an objective response, 
whereas no patients with PD-L1 negative tumour cells responded.11 Similarly, a number of recent 
studies found a greater response rate in patients with PD-L1 positive tumours. In contrast, however, 
these studies also observed objective responses in PD-L1 negative patients.112,113,114,115 These results 
contribute to the growing body of evidence that PD-L1 expression may indicate an increased 
likelihood of response to anti-PD-1/PD-L1 treatment, but is not sufficient to exclude PD-L1 
negative patients from therapy. As more evidence comes to light, the role of PD-L1 expression as a 
predictive biomarker has been questioned for multiple reasons. Most importantly, the validity of the 
data is flawed due to differences in staining methods, antibodies used, cut-off points for 
determining positivity and interpretation of the resulting data.116,117,118 All of which, have led to 
controversy surrounding the role of PD-L1 expression as a predictive biomarker.  
 However, PD-L1 expression by immunohistochemistry is FDA-approved to select patients 
for treatment with pembrolizumab. This success may arise from the markedly increased expression 
of PD-L1 in NSCLC cells compared to other tumour types, including melanoma cells. Kluger et al., 
showed that expression of PD-L1 not only varies between tumour types but also varies within 
patients between stromal cells and tumour cells.116 Thus, these variables need to be considered in 
future evaluations of PD-L1 as a predictive biomarker. Another PD-1 ligand, PD-L2, has been less 
studied, but recently associated with a positive clinical response in patients with head and neck 
squamous cell carcinoma (HNSCC)154. Beside the expression of PD-1 ligands, other biomarkers 
suggested to predict patient response to treatment include white blood cell counts, mutational or 
neoantigen burden and the microbiome.119,120,121,122,123 It has also been suggested that a combined 
biomarker approach may be more effective in predicting response to ICI treatment.124  
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A barrier for biomarker discovery is the atypical response patterns observed in ICI-therapy. 
Unconventionally, tumours treated with ICIs may exhibit ‘pseudoprogression’, in which an initial 
apparent increase in size of a tumour is followed by regression.156 This phenomenom has led to the 
question of whether conventional response evaluation criteria in solid tumours (RECIST), a 
standardized criteria that a number of studies involving ICI-treated patients use, is representative of 
a true response to immunotherapy.135 Traditionally, significant tumour progression on therapy has 
been considered indicative of treatment failure, but, an estimated 10-15% of metastatic melanoma 
patients treated with immune checkpoint inhibitors experience pseudoprogression.155 Retrospective 
findings of pseudoprogression, along with clinical observations in patients undergoing 
immunotherapy, have prompted the development of immune-related response criteria (irRC) and 
immune-related response evaluation criteria in solid tumours (iRECIST).156,157 The intended benefit 
of these developments is to better categorize patients with unconventional response patterns. Even 
so, regulatory authorities have not yet approved these guidelines for use in clinical trials and 
RECIST remains a standard assessment for tumour response to ICI-therapy. With the exception of 
PD-L1 in NSCLC, no single or combination biomarkers have been discovered to clearly predict 
response to ICI therapy.  
 
1.6.2! Biomarkers predictive of toxicity  
Several studies have described biomarkers which may be predictive of toxicity in patients 
undergoing checkpoint inhibitor therapy. Shahabi’s (2013) study, showed two neutrophil-activation 
markers, CD177 and CEACAM1 are promising markers of toxicity.125 In this study, gene 
expression profiling on whole blood samples from melanoma patients treated with ipilimumab 
revealed an increased expression of these neutrophil-associated genes (along with multiple other 
immunologically relevant genes) was associated with gastrointestinal (GI) toxicity. The possible 
role of neutrophils in GI toxicity is backed by an earlier study, which observed an association 
between colonic inflammation prior to initiation of treatment and diarrhoea. Histopathologic 
examination of patient colonic biopsies revealed infiltration of lamina propria by neutrophils, 
presence of crypt abscesses and glandular destructions or erosions in patients at higher risk of GI 
toxicity. Additionally, this study also found an increase in neutrophil-derived fecal calprotein, a 
biomarker of bowel inflammation, was associated with diarrhoea.126  
 Moreover, the appearance of GI irAEs has been linked with elevated interleukin-17 (IL-17) 
serum levels. Two studies evaluating IL-17 levels in ipilimumab-treated melanoma patients have 
reported an association with colitis.127,128 The first, Callahan et al, (2011) reported no significant 
difference in baseline IL-17 serum levels between patients with or without colitis, but significantly 
higher IL-17 serum levels in patients with colitis at weeks 7 and 12.127 In contrast, a second study 
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conducted by Tarhini et al., (2015) found a significantly higher IL-17 serum level at baseline in 
patients who not only developed colitis but any grade 3 irAEs.128 It is unknown whether IL-17 
levels at weeks 7 and 12 correlated with the study of Callahan et al., as blood serum samples were 
not collected during these time points and thus, were unable to be analysed. Since a functional link 
exists between IL-17 and eosinophils, it is not surprising a further correlation between absolute and 
relative eosinophil counts has also been implicated in the occurrence of irAEs.129  
 All of the above studies focus on potential biomarkers that may predict toxicity of GI irAEs. 
There is limited evidence regarding predictive biomarkers of toxicity in other tissues. Furthermore, 
all of these studies described patients treated with ipilimumab, an anti-CTLA-4 inhibitor that 
evidently has a different mechanism of action to PD-1 inhibitors. No studies have been published 
describing biomarkers which reliably predict the development of toxicity in patients treated with 
PD-1 inhibitors. Therefore, the question remains as to whether suggested biomarkers predictive of 
toxicity in patients treated with CTLA-4 inhibitors may predict toxicity in patients treated with PD-
1 inhibitors. Additionally, whether similar biomarkers can predict toxicities in different organs is 
another question yet to be answered. 
 In contrast to studies described above, an alternative approach to identify biomarkers of 
patient response is the investigation of anti-drug antibody production. A previous link has been 
described between the production of ADAs towards mAb therapeutics and an increased incidence 
of adverse events.140,142 However, the precise underlying mechanisms by which mAb therapeutics 
induce the production of ADAs and subsequently, how these anti-drug antibodies confer toxicity is 
yet to be confirmed. At present, toxicological effects are believed to originate from the formation of 
immune complexes between ADAs and therapeutic mAbs.137,158 Interaction of these complexes 
with Fc and complement receptors mediates leucocyte effector functions giving rise to the 
toxicological effects observed in previous studies.158 Theoretically, similar immunogenic 
consequences could be observed in patients treated with nivolumab or pembrolizumab. Thus, one 
understudied approach that may predict the development of toxicity in patients undergoing anti-PD-
1 therapy, is the analysis of anti-drug antibodies. It remains unknown as to whether the formation of 
anti-drug antibodies in patients undergoing ICI-therapy increases their risk of toxicity, a question 
we aim to address in this study.  
 
1.6.3! Role in treatment 
The importance of early diagnosis, clinical monitoring and successful management of irAEs is 
highlighted throughout the literature.2,130,131 In order to optimise patient care and minimise damage, 
it is essential to identify patients at increased risk of toxicity. Although, irAEs have been associated 
with a greater efficacy of ICI-therapy, the risk of debilitating, serious and life-threatening events 
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can outweigh the benefits received from treatment. A recent review by Hamanishi et al., described 
the issues of PD-1/PD-L1 blockade in cancer treatment, emphasizing the identification of 
biomarkers is a crucial step in advancing the application of ICIs.132 They also noted ‘a great deal of 
fundamental, exploratory research remains to be done on areas such as predictive biomarkers for 
therapeutic efficacy and adverse drug reactions.132 As a whole, the literature is in agreement with 
this statement, documenting a need for biomarkers predictive of toxicity. Identifying and validating 
predictive biomarkers will help distinguish patients suitable for ICI therapy, avoiding unnecessary 
toxicity and health-care costs.133 
 
1.7! Conclusion  
In summary, maximising the anti-tumour effect whilst minimising toxicities remains a crucial goal 
in achieving the greatest clinical benefit from immune checkpoint inhibitor therapy. Problematically 
however, increasing stimulation of the patient’s immune system to increase the anti-tumour effect 
simultaneously increases the risk of irAEs, in what can be described as a ‘double-edged sword’ 
effect. In upcoming years, completion of clinical trials of existing and newly developed ICIs will 
increase clinical usage. Yet, several questions remain regarding the underlying mechanisms 
mediating the anti-tumour effects and irAEs induced by this class of agents. Furthermore, no 
biomarkers have been identified to predict the development of toxicity to ICIs, particularly in 
treatment with PD-1 inhibitors. Therefore, to advance current understanding, the overall aim of this 
exploratory study is to investigate clinicopathological indicators, anti-drug antibody levels and 
circulating markers of inflammation that may predict patient outcome.  
 
1.8! Study objectives and thesis outline 
The primary objective of this exploratory study is to improve our understanding of patient response 
to immune checkpoint inhibitors. Thus, this research will be conducted in three parts to investigate 
biomarkers of response (toxicity and efficacy) to anti-PD-1 treatment. The specific objectives are: 
1." To examine clinicopathological indicators of response, patient data will be 
retrospectively reviewed and analysed for associations between patient statistics and 
response.  
2." To examine whether anti-drug antibodies decrease efficacy or increase toxicity, 
therapeutic antibody and anti-drug antibody levels will be measured in patient serum and 
analysed for associations with patient outcome including development of immune-
related toxicities, response and survival.  
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3." To examine circulating markers of inflammation that may predict patient response, 
patient serum will be analysed for blood biomarkers using a commercially available 
antibody array and ELISA. 
Due to time constraints, objective 3 was not completed as part of this project. However, it will be 
completed outside of this project’s time frame to build on preliminary data produced in objectives 1 
and 2. Therefore, the ensuing chapters describe objectives 1 and 2. Chapter 2 describes the 
retrospective review of patient data to explore clinicopathological biomarkers of patient outcome, 
whereas chapter 3 describes the use of an in-house developed ELISA to determine if patients treated 




Based on previous literature we hypothesized that clinicopathological characteristics and levels of 
circulating inflammatory markers will vary between patients with different outcomes to treatment. 
Additionally, patients at a higher risk of developing autoimmune disease will exhibit an increased 
risk of developing toxicities. We also hypothesized that patients who develop anti-drug antibodies 
experience a decrease in treatment efficacy and/or an increase in toxicity. Also, patients who 
produce ADAs and experience decreased efficacy of treatment will have lower circulating drug 


















2! Retrospective review 
 
2.1! Introduction 
As with all newly approved therapeutics, the use of immune checkpoint inhibitors outside of 
clinical trials is anticipated to generate additional data regarding the efficacy and toxicity of these 
agents. Of particular interest, is the use of ICIs in patients that fail to satisfy inclusion criteria of 
initial clinical trials. Following FDA-approval of nivolumab and pembrolizumab in 2014, 
PHARMAC began funding anti-PD-1 treatment for patients in NZ with advanced melanoma (stage 
III and IV) from the 1st of July 2016.150, 161 In clinical trials, immune-related adverse events 
observably display similar characteristics to autoimmune conditions, however, their underlying 
etiology is yet to be determined.83 Demographic characteristics are known contributors to the onset 
of autoimmune disease, but, thus far, it is unknown as to whether these variables factor in the 
development of irAEs. In particular, women and elderly individuals represent high-risk populations 
for autoimmune conditions.84,85 Owing to this increased risk and the observed similarities of 
autoimmune conditions with irAEs, we sought to determine whether demographic characteristics 
may predict patient outcome. To date, no demographic characteristics have been associated with 
patient response or survival. Therefore, we focused on their association with toxicity. Specifically, 
we hypothesise that patients at an increased risk of developing autoimmune disease also have an 
increased risk of developing irAEs during ICI-therapy.  
Alternatively, it has been suggested that blood parameters may act as preferential 
biomarkers for response to ICI-therapy.123,124 The underlying mechanism of checkpoint inhibition is 
unknown, but, it is clear that white blood cells, play an important role. Neutrophils, lymphocytes 
and eosinophils have each been implicated in patient response and the development of irAEs, but, 
the interplay between blood parameters and patient outcome is yet to be confirmed.123,125,129 To 
investigate the possible use of blood biomarkers in ICI-therapy, this chapter analysed the complete 
blood counts of ICI-treated patients and their association with patient outcome.  
An exploration into the relationship of patient clinicopathological variables with patient 
outcome is of clinical relevance to determine patients suitable for ICI therapy. Exploration in real-
life patients is particularly warranted given the lack of published literature investigating ICIs 
outside of regulatory clinical trials. Ideal biomarkers will select patients for treatment based on an 
increased likelihood of responding to treatment or a decreased risk of developing severe toxicity. 
Ultimately, the discovery of such biomarkers will prevent a subset of patients from undertaking an 
expensive, ineffective treatment that carries potential life-threatening toxicity. Therefore, the 
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primary aim of this chapter was to determine whether clinicopathological characteristics predict 
patient outcome (in terms of patient response, survival and the development of toxicity) and 
examine their potentiality as a biomarker(s) for ICI therapy in clinical practice.  
 
2.2! Materials and Methods 
2.2.1! Study Participants 
This study involved patients treated for stage III or IV metastatic melanoma with nivolumab or 
pembrolizumab by Canterbury Regional Cancer and Haematology services. Patients were eligible 
for inclusion if they had a confirmed diagnosis of stage III or IV metastatic melanoma and received 
at least one dose of nivolumab or pembrolizumab at Christchurch Hospital, New Zealand. Patients 
unable to provide informed consent or under 18 years of age were excluded from the study. All 
participants gave written informed consent for use of available clinicopathological data for 
scientific purposes. Ethical approval for this study was obtained from the Southern Health and 
Disability Ethics Committee of New Zealand (approval 16/NTB/139).  
 
2.2.2! Treatment Regimen  
Patients were treated at the Oncology unit in Christchurch Hospital, New Zealand, with nivolumab 
or pembrolizumab as a monotherapy for metastatic melanoma according to national PHARMAC 
guidelines. Patients were treated as per standard of care treatment. Nivolumab was administered at a 
dose of 3mg/kg intravenously over 60 minutes every 2 weeks (Q2W). Pembrolizumab was 
administered at a dose of 2mg/kg intravenously over 30 minutes every 3 weeks (Q3W). Treatment 
was continued until: (1) disease progression according to RECIST version 1.1 by radiographic 
assessment, primarily computed tomography (CT) scan; and/or (2) unacceptable toxicity as 
assessed by the practicing clinician. 
 
2.2.3! Data collection 
With approval from the Southern Health and Disability Ethics Committee, New Zealand, eligible 
patients were identified for review from the Christchurch Hospital Medical Oncology database. 
Patients treated with nivolumab (Q2W) or pembrolizumab (Q3W) as a monotherapy for metastatic 
melanoma (stage III or IV) between 1st July 2016 to 30th June 2017 were retrospectively reviewed 
using electronic medical records and clinician notes. Collection of data was completed after 
appropriate training and all information was collected and collated under the supervision of Dr. 
Matthew Strother (Medical Oncologist and Clinical Pharmacologist). The following clinical data 
was collected: patient demographics, medical history, disease status, prior treatment, current 
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therapeutic regimen, response to treatment, laboratory blood values and toxicity events. The data 
cut-off point was 30th June 2017. All patients were followed up until death, or data collection 
endpoint.   
 
2.2.4! Haematological Parameters 
Haematological parameters were derived from laboratory blood tests routinely performed at the 
Canterbury District Health Board (CDHB) Canterbury Health Labs or Southern District Health 
Board (SDHB) Southern Community Laboratories. Resulting complete blood counts were obtained 
from patient electronic medical records. Complete blood counts were recorded for patients prior to 
treatment (baseline) and throughout treatment, until 28 days after discontinuation of treatment or 
death. The normal range of complete blood count values in healthy individuals were obtained from 
the Christchurch Hospital Medical Oncology database. Baseline complete blood counts were used 
to calculate white blood cell ratios. Specifically, neutrophil to lymphocyte ratio (NLR) was 
calculated by division of neutrophil counts by lymphocyte counts and lymphocyte to monocyte ratio 
(LMR) was calculated by division of lymphocyte counts by monocyte counts.  
 
2.2.5! Response Evaluation 
To assess response to treatment, patients underwent CT scanning prior to treatment (baseline), 
followed by restaging CT scanning at 12 week intervals after first infusion of drug. Initial baseline 
assessments and subsequent response to treatment was determined by a medical practitioner 
according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1. Responders 
were classified as patients that met RECIST criteria for complete or partial response. Non-
responders were classified as patients that met RECIST criteria for stable or progressive disease. 
Time to progression was calculated from the date of starting treatment to the earliest CT scan 
showing disease progression by RECIST criteria or death. The best overall response was defined as 
the best response recorded from the start of treatment until disease progression. 
 
2.2.6! Toxicity Assessment 
Data collection of adverse events from electronic medical records and clinician notes was 
completed for events occurring throughout treatment until 28 days after cessation of treatment or 
until commencement of subsequent alternative treatment or death. Data collected included the date 
the event was reported, clinical presentation, grade and treatment plan. The severity of events was 
graded according to National Cancer Institute Common Terminology Criteria for Adverse Events, 
version 4.0 (CTCAE v4.0). Grading was completed by a medical practitioner at time of event 
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reporting, otherwise, grades were retrospectively assigned by the investigator based on description 
of events by the practicing clinician and CTCAE v4.0. IrAEs were defined as adverse events of 
unknown cause with a potential immunologic basis, associated with drug exposure.  
 
2.2.7! Statistical analysis 
All analyses were carried out using Microsoft Excel version 15.38 and GraphPad Prism version 6.0 
(San Diego, CA, USA). Descriptive statistics were used to summarize clinicopathological data 
including patient demographics and treatment characteristics. Data was summarized as n (%) for 
categorical variables and as median (range) for continuous variables. The Chi-square test was 
applied to categorical variables to determine any significant differences between groups. Unpaired 
t-tests were used to compare continuous variables. Kaplan-Meier curves were used to estimate 
progression-free survival. Log-rank test was used for comparison of progression-free survival 
among variable factors. All statistical tests were two-sided and p values <0.05 were considered 
statistically significant.  
 
2.3! Results 
2.3.1! Patient Population 
2.3.1.1!Baseline Demographics   
Between 1st July 2016 to 30th June 2017, thirty-two patients were treated with nivolumab or 
pembrolizumab as a monotherapy for metastatic melanoma (stage III or IV) at Christchurch 
Hospital, New Zealand. A detailed listing of clinicopathological characteristics of these patients is 
presented in Table 2.1. The median age at data cut-off point was 70 years (range, 30-86 years), with 
male predominance (72%). Patients were primarily New Zealand European in ethnicity (91%). 




On retrospective review, 26 (81%) patients had pre-existing comorbidities. Three patients (9%) had 
a previously diagnosed autoimmune condition upon starting treatment, namely psoriasis, 
rheumatoid arthritis or multiple sclerosis. Fourteen (44%) patients had inflammatory conditions. 
The most common inflammatory condition was gastro-esophageal reflux disease (GORD) occurring 
in 6 patients, followed by gout (3 patients), pseudogout (2 patients) and asthma (2 patients). 
Extrinsic allergic alveolitis (hypersensitivity pneumonitis) was present in one patient. Nearly a third 
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of patients (31%) had a previous non-melanoma cancer. 50% these patients (5 out of 10) had non-
melanoma skin cancers, presenting as squamous and basal cell carcinomas. Bladder, blood, cervical 
and prostate cancer represented the other cancer types recorded for this patient cohort. Over a third 
of patients (34%) had cardiovascular conditions. Coronary artery disease was reported for 3 
patients, with a further 7 patients noting a history of myocardial infarctions, supraventricular 
tachycardia, angina or transient ischemic attacks. Other notable comorbidities of this patient cohort 




At the beginning of the study, 17 (53%) patients had received prior therapy for metastatic 
melanoma in the form of radiotherapy, immunotherapy and/or targeted therapy. Radiotherapy was 
the most common pre-treatment (15 patients), followed by immunotherapy (3 patients) and targeted 
therapy (1 patient). All 3 patients who received prior immunotherapy underwent treatment with 
immune checkpoint inhibitors before commencement of the study period. Patients received ICI-
therapy through privately funded treatment or as part of a clinical trial. One patient was treated with 
pembrolizumab monotherapy, one patient underwent sequential ipilimumab and pembrolizumab 
monotherapy and one patient received a combination therapy of ipilimumab and pembrolizumab. 
Irrespective of surgical intervention, over half (53%) of patients had received at least one prior 
therapy and two patients had received two forms of prior therapy. In the current study, 21 patients 
(66%) received nivolumab and 10 patients (32%) received pembrolizumab. One patient received 
both PD-1 inhibitors sequentially. A median of five treatment cycles per patient was administered 
and the maximum number of cycles administered to a patient during the study period was 26. As of 
the data collection endpoint, treatment with nivolumab or pembrolizumab was ongoing in 16 
patients (50%).  
 
Table 2.1: Summary of the clinicopathological data for metastatic melanoma patients used in 
this retrospective study 
Patient characteristic Total (n = 32) 
Age (years), median (range) 70 (30-86) 
Sex  
Female 9 (28%) 
Male 23 (72%) 
Ethnicity   
New Zealand European (Pakeha) 29 (91%) 
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European, not further defined 2 (6/%) 
Unknown 1 (3%) 
Body mass index, median (range) 26.6 (18.1-44.2) 
Clinical stage  
III 6 (19%) 
IV 26 (81%) 
Brain metastases  
Yes 9 (28%) 
No 23 (72%) 
Anti-PD-1 monotherapy   
Pembrolizumab 10 (31%) 
Nivolumab 21 (66%) 
Pembrolizumab/Nivolumab 1 (3%) 
No. of cycles, median (range) 5 (1-26) 
Prior therapy  
Chemotherapy 0 (0%) 
Targeted therapy (BRAF+MEK inhibitor) 1 (3%) 
Immunotherapy 3 (9%) 
Radiotherapy 15 (47%) 
No. prior therapy  
0 15 (47%) 
1 15 (47%) 
2 2 (6%) 
Comorbidities  
Autoimmune condition 3 (9%) 
Inflammatory condition 14 (44%) 
Cardiovascular disease 11 (34%) 
Non-melanoma cancer 10 (31%) 
Any 26 (81%) 
Overall status at last follow-up  
Alive 29 (91%) 
Deceased 3 (9%) 
Values are number and percentage unless otherwise stated 
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2.3.2! Haematological Parameters 
2.3.2.1!Baseline Values 
Over half of all patients reviewed had at least one complete blood count (CBC) abnormality prior to 
treatment (18 patients, 56%). A detailed summary of complete blood count values for patients 
included in this study is shown in Table 2.2. Baseline eosinophil and basophil counts were 
unavailable for analysis for three patients and 21 patients, respectively.  
 
Table 2.2: Complete blood count values of patients included in this study  
Haematological Parameter Normal Range 
Total (n = 32) 
Range Mean 
Red cell parameters    
Haemoglobin (g/L) 115-175 99-166 132.5 
Haematocrit (%) 0.35-0.52 0.31-0.49 0.41 
Mean corpuscular volume (fL) 80-99 77-112 89.6 
Mean cell haemoglobin (pg) 27-33 23-36 29.3 
White cell parameters    
White cell count (x109/L) 4-11 3.4-12.3 7.1 
Neutrophils (x109/L) 1.9-7.5 2.4-9.1 4.8 
Lymphocytes (x109/L) 1-4 0.36-3.6 1.45 
Monocytes (x109/L) 0.2-1 0.1-1.3 0.6 
Eosinophils (x109/L)a 0.0-0.5 0.0-0.5 0.19 
Basophils (x109/L)b 0.0-0.20 0.0-0.23 0.09 
Other parameters    
Platelets  150-400 134-474 294.9 
Ranges include male and female data 
a data missing from three patients 
b data missing from 21 patients 
 
   
 
2.3.3! Efficacy of treatment 
At data cut-off point, response assessment to anti-PD-1 treatment was available for 27 patients. 5 
patients were unevaluable for response as they were yet to undergo their first restaging scan. Of the 
evaluable 27 patients, 11 patients experienced disease progression, 12 had a partial response to 
treatment and 4 patients exhibited stable disease as a best overall response, according to RECIST 
criteria (Table 2.3). One responder exhibited pseudo-progression, in which progressive disease was 
observed at the first restaging scan, followed by resolution of the progressive disease in a 
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subsequent scan. The progression-free survival curve of all patients included in this study is shown 
in Figure 2.1. The median PFS of all patients was 6 months. At last follow-up, 29 patients (91%) 
remained alive and no deaths were drug related.  
 
Table 2.3: Best overall response of patients reviewed  
Best Overall Response Total (n = 32) 
Partial response 12 (37.5%) 
Stable disease 4 (12.5%) 
Progressive disease 11 (34%) 
Response not evaluated 5 (16%) 
 
 
Figure 2.1: Progression-free survival curve of all patients included in this study (n=32).  
 
2.3.4! Toxicity 
2.3.4.1!Overview   
IrAEs of any grade were observed in 29 (91%) patients. The most commonly reported events 
included fatigue, rash, dyspnea and constipation, as shown in Table 2.4. Events affecting the skin 
were most frequently observed, with 41% of all patients reviewed experiencing dermatological 
effects. The pulmonary and gastrointestinal system were the second and third most adversely 
affected organ systems with 34% and 25% of patients experiencing pulmonary and GI events, 
respectively. Events of the endocrine system were less frequently reported, affecting 19% of all 
patients. The percentage of organ-specific events affecting our patient cohort is shown in Figure 
2.2. During the study period, 19 (59%) patients presented with irAEs affecting two or more organs, 























either concurrently or sequentially. The majority of events were low-grade. High-grade events were 
infrequently observed, with 1 patient experiencing a grade 3 skin rash, another requiring 
hospitalization due to pneumonitis and one experiencing severe fatigue.  
 
 
Figure 2.2: Distribution of irAEs by organ. The percentage of patients affected by irAEs (all 
grades) across different organ systems.  
 
Table 2.4: Incidence of common immune related adverse events in all patients (N=32). 
Percentages represent the occurrence of an event in all patients including patients who experienced 
multiple irAEs. 
Event Any Grade Grade 3-4 
Fatigue 22 (69%) 1 (3%) 
Rash 11 (34%) 1 (3%) 
Dyspnea 8 (25%) 0 (0%) 
Constipation 7 (22%) 0 (0%) 
Cough 6 (19%) 0 (0%) 
Nausea 6 (19%) 0 (0%) 
Pruritus 6 (19%) 0 (0%) 
Diarrhea 4 (13%) 0 (0%) 
 
2.3.4.2!Management of irAEs 
IrAEs were generally managed with supportive care, withholding of treatment or intervention with 
corticosteroids. Of the 29 patients who experienced an irAE, seven (24%) required treatment with 
steroids. Appearance of a skin rash was the predominant reason for steroid initiation (5 patients), 
followed by pneumonitis (one patient), cough (one patient) and a hypersensitivity reaction (one 
patient). It should be noted the patient who was prescribed steroids for pneumonitis was the same 























occurred sequentially and separate steroids were prescribed for each event. Prednisone was most 
frequently prescribed, followed by hydrocortisone and clobetasone. Other interventions included 
aqueous creams, thyroid hormone, carbimazole, laxatives, antihistamines, anti-emetics, analgesics, 
and nonsteroidal anti-inflammatory drugs (NSAIDs).  
Four (13%) patients had treatment withheld due to irAEs. One patient delayed cycle 23 by 1 
week due to grade 1-2 transaminitis. No further intervention was required and the patient was able 
to re-commence ICI-therapy. One patient withheld, restarted and later switched anti-PD-1 therapy 
from nivolumab to pembrolizumab, due to a grade 3 skin rash. In this case, the initial use of 
clobetasone and hydrocortisone, in conjunction with treatment discontinuation resulted in a 
significant improvement in rash. A grade 3 rash recurred upon restarting of nivolumab, prompting 
the prescription of high dose prednisone (80mg). High dose steroid use and the replacement of 
nivolumab with pembrolizumab resulted in complete resolution of the rash and the ability to 
continue treating the patient with ICIs. One patient withheld cycle 2 due to esophagitis and gastritis, 
but was not restarted on treatment due to disease progression. One patient was hospitalized due to 
pembrolizumab-induced pneumonitis, resulting in a delay of cycle 3 of treatment by 2 weeks. 
Following ICI-therapy delay and intervention with corticosteroids, the patient recovered from 
pneumonitis showing no further symptoms during the study period. In all four cases, withholding of 




Skin was the most adversely affected organ with 13 (41%) patients experiencing dermatological 
irAEs. Events were primarily low-grade and high-grade skin irAEs were not observed, with the 
exception of one grade 3 skin rash. Clinically, the dermatological events observed in this study were 
rash, pruritus and psoriasis, descending in order of prevalence. Eleven (34%) patients developed a 
skin rash during treatment, typically following the first or second infusion. The median time to rash 
presentation was 3 weeks (range, 1-13 weeks) and maculopapular erythematous rashes were 
commonly described. Pruritus was observed concurrently with rash in five patients, but also 
manifested in one patient without rash toxicity. A detailed summary of the demographic and clinical 
characteristics of patients who presented with rash during this study are shown in Table 2.5. One 
case of psoriasis was recorded for a patient with pre-existing psoriasis who experienced an 
exacerbation of the condition upon commencing pembrolizumab, followed by symptom 
stabilization. No further dermatological events were reported in this study.   
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Table 2.5: Demographic and clinical characteristics of patients presenting with rash toxicity during anti-PD-1 treatment  
Case Age Sex Grade Week of onset, (cycle 
of anti-PD-1 therapy) 
Clinical presentation Location Cessation of 
drug 
Steroid intervention 
1 83 m 1 3 (cycle 2) macular erythematous, 
desquamation, eczematous 
arms, legs, torso no yes  




no yes  
3 37 f 1-2 4 (cycle 3) not reported not reported no no 
4 59 m 1 10 (cycle 3) macular forearms no no 
5 71 m 1 6 (cycle 2) not reported legs no no 
6 69 m 1 1 (cycle 1) macular erythematous arms, legs, torso, 
trunk (back), 
scalp 
no yes  
7 69 m 1 1 (cycle 1) not reported trunk (chest) no yes 
8 75 m 1-2 2 (cycle 1) macular papular arms no no 
9 68 m 3 5 (cycle 3) maculopapular 
erythematous, dry 
desquamation 
arms, legs, torso, 
back, neck, face 
yes yes  
10 73 m 1-2 13 (cycle 4) mild petechial legs no no 
11 39 f 1-2 3 (cycle 2) not reported forearms no no 
         







Respiratory events were the second most reported, with irAEs reported in 11 (29%) patients. 
Following commencement of anti-PD-1 therapy, dyspnea (shortness of breath) was reported by 
eight (25%) patients. Six (19%) patients developed a cough throughout therapy and, of these 
patients, one developed a productive cough. All dyspnea and cough events were low grade. One 
patient presented to hospital with a confirmed case of high grade pembrolizumab-induced 
pneumonitis. Two additional patients developed chest infections however, it was unclear as to 
whether the pneumonitis event in these patients was an infective process or secondary to anti-PD-1 
therapy.  
 
2.3.4.5!Gastrointestinal events  
25% of patients experienced irAEs affecting the gastrointestinal tract. During treatment, four 
patients reported diarrhea. In all four cases, diarrhea was low grade (<6 diarrheal bowel movements 
per day over baseline). Two additional patients reported diarrhea during the study period but these 
events were deemed not related to treatment, due to existence prior to therapy or causation of 
symptoms through the use of anti-constipation medication. Six patients (19%) experienced nausea 
throughout treatment and one patient exhibited grade 2 vomiting (4 episodes within 24hrs). A 
further patient, not experiencing nausea, reported one episode of vomiting. Seven patients (22%) 
reported constipation throughout treatment, however, in two of these patients the constipation event 
was deemed not related to treatment, instead, attributed to the use of opiate analgesics. Three 
patients (9%) developed abdominal pain upon starting treatment.  
 
2.3.4.6!Endocrine events  
In this study, endocrine events reported were low grade and generally related to the thyroid gland. 
Alteration of thyroid gland function was detected in six (19%) patients. Specifically, 
hypothyroidism was detected in three patients and hyperthyroidism in one patient. Subclinical 
hypothyroidism and hyperthyroidism was identified in two patients with low or high levels of 
thyroid-stimulating hormone, respectively. One case of adrenal insufficiency was reported in a 
patient. However, the insufficiency was attributed to cessation of hydrocortisone, rather than an 





Of all the adverse events described in this study, fatigue was the most frequently reported, affecting 
22 (69%) patients. Less common events reported included infusion-related reactions, 
musculoskeletal events and hematological events. Two (6%) patients experienced hypersensitivity 
reactions, both attributed to pembrolizumab infusion. In the first case, a 59-year-old male 
experienced a reaction during cycle 3 of treatment requiring immediate intervention with 
intravenous steroids and antihistamines. The second case, which required no intervention, involved 
a 57-year-old female who experienced a mild reaction following cycle 1 of treatment. Pain was 
reported for 14 (44%) patients throughout treatment, but, typically preceded ICI-therapy or was 
attributed to disease progression. However, three patients specifically reported joint pain 
(arthralgia) in response to anti-PD-1 therapy. In one patient, arthralgia was a recurring symptom of 
underlying arthritis. Another patient also experienced a flare in a pre-existing inflammatory 
condition, noting an increase in gout-related symptoms. At the end of the study period, one patient 
with elevated creatine levels and one patient with abnormal liver function tests were noted to have 
potential drug-related nephritis or hepatitis, respectively. Other effects reported included a loss of 
appetite (five patients), swelling (three patients) and anemia (two patients). 
 
2.3.5! Association of clinicopathological variables, efficacy and toxicity  
No statistically significant differences were found between clinicopathological variables and patient 
outcome including patient response, survival and development of toxicity. In particular, no 
statistically significant differences in progression-free survival were found between males and 
females or between patients over the age of 70 and patients under the age of 70 (Figure 2.3). There 
was also no statistically significant difference in progression-free survival between patients with 
different white blood cell ratios, as shown in Figure 2.4. Additionally, no significant difference in 
progression-free survival was found between patients who developed a rash and patients who did 
not develop a rash during ICI-therapy (Figure 2.5). Similarly, there was no statistically significant 
differences in baseline haematological values of responders versus non-responders (Figure 2.6) and 
patients who developed a rash versus patients who did not develop a rash (Figure 2.7) No 
statistically significant differences were found between clinicopathological variables and the 
development of toxicity in any organ or of any grade. No further statistical analysis was possible 


















Figure 2.3: Progression-free survival of patients included in this study stratified by 















Figure 2.4: Progression-free survival of patients included in this study stratified by baseline 
white blood cell ratios. Kaplan-Meier curves for patients stratified by neutrophil to lymphocyte 
ratio (NLR) (A) and lymphocyte to monocyte ratio (LMR) (B). 
 
 
Figure 2.5: Progression-free survival of patients included in this study stratified by rash 
toxicity.  
 


































































































































Figure 2.6: Baseline peripheral white blood cell counts of responders and non-responders. 
Selected baseline peripheral white blood cell counts of responders (n=12) and non-responders 
(n=16) are presented as box and whisker plots. Whiskers indicate minimum and maximum values 
for each group and the edge of the box represents the twenty-fifth and seventy fifth quartiles. 
Median values are indicated by a line inside the box. No significant differences between white 




Figure 2.7: Baseline peripheral white blood cell counts of patients who developed rash versus 
patients who did not develop rash. Selected white blood cell counts of patients who developed a 
rash (n=11) and patients who did not develop a rash (n=21) are presented as box and whisker plots. 
Whiskers indicate minimum and maximum values for each group and the edge of the box represents 
the twenty-fifth and seventy fifth quartiles. Median values are indicated by a line inside the box. No 
significant differences between white blood cell counts were found between patients who developed 




































The production of immune-related adverse events and low efficacy in a subset of patients poses a 
significant downfall to ICI-therapy. To prevent a proportion of patients exposed to an ineffective 
and potentially dangerous therapy, there is an unmet need for biomarkers that will select appropriate 
patients for treatment. This chapter reviewed patients treated with anti-PD-1 monotherapy to 
identify clinicopathological markers associated with patient outcome. Specifically, this chapter 
sought to determine the potential for clinicopathological biomarkers to reliably predict patient 
survival, response and/or development of toxicity.  
 
The only exclusion criteria for this retrospective review was the exclusion of patients under the age 
of 18. Clinical trials completed as part of the regulatory approval process of nivolumab or 
pembrolizumab excluded patients with one or more of the following characteristics; brain 
metastases, a history of autoimmune disease, prior therapy (particularly with antibodies that 
modulate T-cell function), conditions requiring immunosuppressive medications and inadequate 
hematologic, hepatic or renal function. Early clinical trials also excluded patients with significant 
comorbidities and/or prior malignancies.10,11,19,20,21 If this exclusion criteria were re-applied to our 
study population, 72% of patients would be ineligible for participation in early trials of anti-PD-1 
agents. The high percentage of patients unable to fulfil inclusion criteria of early trials may be, to 
some extent, attributed to the higher median age of patients in this study (70 years).10,11 
Unsurprisingly, as patients age, the risk of developing significant comorbidities, impaired organ 
function and/or acquiring conditions that require immunosuppressive medications increases, 
rendering these patients ineligible for various clinical trials.159 Yet, oncologists will regularly 
encounter these patients in real life clinical settings, highlighting a need for safe and effective 
treatment options. To explore how patients who would be ineligible under clinical trial protocols 
respond to ICI-therapy, all patients were included in the current study, given they were above 18 
years of age.  
 
Data is beginning to emerge from studies examining the efficacy and toxicity of anti-PD-1 agents in 
specialist patient populations, such as those with organ transplants and various autoimmune 
diseases.160,162,164 Patients with autoimmune conditions are typically excluded from clinical trials of 
ICIs, due to safety concerns. Treatment and management of autoimmune disease requires 
suppression of the immune system, an opposite effect to that induced by immune checkpoint 
inhibitors.1,160 Thus, due to their mechanism of action, ICIs may exacerbate underlying autoimmune 
conditions and increase the risk of treatment-induced irAEs. Unfortunately, the prevalence of 
autoimmune disease is increasing, particularly in industrialized countries, affecting a large number 
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of individuals who may require oncological treatment with ICIs.163 Only recently has data been 
published reporting the efficacy and safety of anti-PD-1 agents in patients specifically with 
autoimmune disease.160,164 A systematic review conducted by Abdel-Wahab et al, (2016) found that 
28.9% of patients with underlying autoimmune disease experienced flares of their condition upon 
commencement of ICI-therapy.160 In the current study, a low number of participants had an 
underlying autoimmune disease (n=3) and, in line with previous literature, 1 in 3 patients had an 
exacerbation of underlying autoimmune disease. Importantly, no high-grade irAEs were observed in 
this subset, demonstrating that ICIs may safely be used without exacerbation of disease or risk of 
developing serious toxicities. The efficacy of ICI treatment in this subset is yet to be established, 
with a best overall response of stable disease observed in two patients in this study. However, due 
to the small number of patients with autoimmune disease in this study, no conclusions can be 
drawn. Studies investigating a greater number of participants are required to determine the risk-
benefit profile of ICI-therapy in this specialist population.  
 
It is well established that females and individuals of an older age have a higher risk of developing 
autoimmune disease.84,85 Interestingly, the three cases of patients with autoimmune disease in this 
study, described two males and one female of a typically younger age (36, 39 and 58 years old). 
Nonetheless, due to the observed symptomatic similarities between autoimmune disease and irAEs, 
we hypothesized that risk factors of autoimmune disease would also factor in the development of 
irAEs during ICI-therapy. In opposition to this hypothesis, our study found no significant 
differences between the development of irAEs (of any grade, or in any organ) and patient age or 
gender, further, supporting the idea that the underlying pathophysiology between the two conditions 
is different. Our patient cohort was predominately male (72%) and of an older age (median=70). 
This is to be expected as, in New Zealand, the risk of developing melanoma increases with age and 
males are more commonly affected. Data from the Ministry of Health NZ (2013-2015), show 
melanoma was most frequently diagnosed in male individuals, particularly those aged 70-74.165 
However, the gender imbalance observed in this study, is markedly different from previous data. Of 
the patients diagnosed with melanoma in NZ in 2015, 55% were male and 45% were female.165 This 
may be explained by a trend that has been observed overseas, describing a faster increase in the 
incidence of melanoma in men than women.166 However, it is most likely attributed to chance. 
 Our study showed no significant differences in patient response or survival between females 
and males or patients under the age of 70 versus patients over the age of 70. Given the rise of 
melanoma diagnoses with age, the efficacy of immune checkpoint inhibitors in elderly patients is of 
particular clinical relevance. No conclusions can be drawn from our study, due to limited numbers, 
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but our data is in line with previous literature, which indicates ICIs are an equally efficacious 
treatment option for geriatric melanoma patients.167    
 
In this study consisting of patients deemed ineligible or eligible for earlier clinical trials (n=32), 
44% responded to treatment. This figure is in line with previous studies, albeit slightly higher.10,11  
Patients who responded to treatment according to standard RECIST criteria, appeared to maintain 
their response throughout the study period. During the study period, only one patient who achieved 
a response went on to experience disease progression. Caution should be exercised however, due to 
a relatively short study period (12 months). Nonetheless, this supports previous studies, which 
indicate anti-PD-1 agents induce sustained responses, a characteristic which confers an advantage 
over conventional treatment options. It has been suggested that the ‘memory’ of the immune system 
is responsible for the formation of long-lasting responses.168 As these agents have been newly 
approved, the potential maximal response duration is yet to be determined. A further question exists 
as to whether these agents may be tantamount to cures for some individuals. If so, studies into the 
appropriate duration of treatment should be conducted to determine whether patients could cease 
therapy to prevent the occurrence of serious irAEs.  
 
Our study reported a high incidence in the development of immune-related adverse events, 
observing events in 91% of patients. Previous studies indicate that up to 70% of patients undergoing 
anti-PD-1 treatment experience irAEs.2 This markedly increased incidence may be due a number of 
factors. Firstly, it is well established that the incidence of irAEs in clinical trials of immune 
checkpoint inhibitors is underreported. Some studies only report irAEs that occur above a certain 
threshold, ranging from above >1% and 5-10%.80 More importantly, a limitation in this field of 
research is the absence of a uniform definition of an irAE. No standardized criteria exists to 
determine whether adverse events are of an immune-related origin or are the result of alternate 
aetiology.2 In our study, we classified irAEs as adverse events of unknown cause with a potential 
immunologic basis, associated with drug exposure. However, discrepancies in definition can make 
comparison of incidences between studies difficult. Additionally, the FDA warn that, due to 
differing conditions of conducted clinical trials, adverse event rates may not reflect the rates 
observed in general practice.75,76 The use of these agents in real-life patients has been suggested to 
contribute to an increased prevalence of irAEs in general practice.81 An alternative hypothesis to the 
increased incidence of irAEs observed in this study, is that patients normally excluded from clinical 
trials are at greater risk of developing toxicity. However, this possibility requires further 




Despite differences in overall incidence, the type and frequency of irAEs observed in this study are 
in line with patterns of occurrence in previous studies. Events commonly reported in earlier studies 
such as fatigue, rash, and constipation, largely affected our patient cohort.2,10,11,21 In particular, skin 
rashes were the most frequently reported organ-specific event. A trend amongst previous literature 
is the sequential appearance of events affecting different organ systems. Skin irAEs tend to appear 
early during therapy, followed by gastrointestinal events and lastly by endocrine and hepatic 
events.2,134 A similar trend was observed in the present study. Nine of the 13 patients who presented 
with dermatological events reported rash, pruritus or psoriasis as their first occurring event. 
Additionally, gastrointestinal, endocrine or hepatic symptoms were generally described later in 
therapy. The majority of events occur within the first 12 weeks of treatment (before an initial 
restaging scan), but the appearance of irAEs has been reported up to 1 year after starting anti-PD-1 
treatment.2,181 Even though our data collection period spanned over 1 year, the majority of patients 
reviewed started treatment within this period, rather than at the beginning of the study. Owing to 
this pattern of appearance, a longer study duration or a follow up study of these patients would be 
interesting to observe whether events typically occurring later in treatment appear.  
Consistent with previous studies, uncommon events were less prevalent. Furthermore, no 
rare irAEs such as Gullian-Barre syndrome, Stevens-Johnson syndrome or aseptic meningitis were 
observed in our study.2 Presumably, these absences are due to the design of this exploratory study 
which lacks the power to detect less common events, particularly rare events occurring in less than 
1% of patients. In order to increase the power of future studies to detect rare events, a larger sample 
size could be analysed. The severity of events in our study also followed a similar pattern to 
published literature. Grade 3-4 events have been documented for 12-20% of patients treated with 
nivolumab or pembrolizumab and three patients (9%) experienced severe irAEs in the present 
study.169 The slightly lower incidence may be attributed to a small sample size, but may denote an 
increased awareness of potential irAEs and their appropriate management by physicians. As more 
cohort or case studies are published, physicians become increasingly aware of the potential irAEs 
that may occur and importantly, learn how they may be effectively treated or managed before their 
severity increases.  
 
A controversial link has been reported between the development of irAEs (particularly 
dermatological events) and response to ICI-therapy.103,104,105 To explore this theory, we compared 
the progression-free survival of patients who developed a rash during therapy to those who did not 
develop a rash in our patient cohort. We observed no significant difference between these two 
subgroups (p=0.1466) but, interestingly, noted a trend towards improved PFS of patients who 
developed a rash. Caution must be exercised when interpreting this result due to the small number 
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of patients in each subgroup, specifically 11 patients who developed rash versus 21 patients who did 
not. While a statistically significant association between rash and patient response to anti-PD-1 
therapy has been described previously in multiple studies, these findings need to be validated in 
studies incorporating a larger number of study participants. Although an interesting trend towards 
improved progression-free survival was seen in patients who developed a rash, our findings can 
neither confirm nor negate this proposed link.  
 
Additionally, pseudo-progression was observed in one patient in this study. Initial enlargement of a 
tumour in patients with unconventional response patterns is thought to be mediated by lymphocyte 
infiltration into the tumour, rather than tumour cell proliferation.156 Interestingly, when monitoring 
the lymphocyte counts of this particular patient in our study, an increase in circulating lymphocytes 
from baseline occurred at the time of apparent disease progression. Whereas, before the ensuing CT 
scan, which showed regression of the tumour, the patient’s lymphocyte count had decreased. In this 
study however, we did not investigate the tumour microenvironment directly and therefore, it is 
unknown as to whether an increase in circulating lymphocytes correlated with increased tumour 
infiltration of lymphocytes. In future studies, an investigation into the association of blood 
parameters with pseudoprogression, rather than conventional response patterns may assist in the 
development of response criteria and differentiation between true progression and 
pseudoprogression.  However, as to whether the patient case in this study had an increased 
infiltration of lymphocytes into the tumour is unknown. A biopsy of the tumour with subsequent 
immunohistochemistry could have been applied to investigate blood parameters within the tumour 
microenvironment.  Preliminary data from a recent study found patients who experienced 
pseudoprogression tended to be younger in age than those who did not.170 This finding is yet to be 
validated, but serves as an indication that clinicopathological factors may contribute to 
pseudoprogression. The present study reports one case of pseudoprogression in an 80-year-old 
female and thus, is unable to contribute to this theory, but it is important to recognize that 
pseudoprogression may also occur in elderly patients.  
 
Research investigating peripheral blood biomarkers has proposed an association between various 
haematological parameters and patient response, survival or the development of toxicity.123,124,125,129 
In particular, a lower neutrophil to lymphocyte ratio (NLR) has been associated with a shorter 
progression-free survival.171 Conversely, our study found no significant difference in PFS between 
patients with a NLR above three and patients with a NLR below three. Furthermore, a study 
published earlier this month (October 2017), reported the first analysis of the lymphocyte to 
monocyte ratio (LMR) in patients treated with immune checkpoint inhibitors.172 In this study, a 
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baseline LMR of less than 1.7 was associated with improved PFS and overall survival in metastatic 
melanoma patients treated with pembrolizumab. The present study found no significant difference 
in PFS, but similarly noted a trend towards improved PFS in patients with a LMR below 1.7. 
Furthermore, in contrast to previous studies our study detected no significant differences at baseline 
between haematological parameters of responders versus non-responders. These results may be due 
to small numbers preventing the ability of significant associations to be detected, however, 
highlights the idea that patients with different baseline blood values may respond the same to 
therapy or vice versa. Additionally, this data supports the idea that circulating blood biomarkers 
previously associated with patient outcome, may not possess the specificity or reliability to select 
patients for treatment. Peripheral blood markers are preferentially sought after in biomarker studies 
due to their ease of accessibility and routine measurement in clinical practice. However, in the 
instance of ICI-therapy blood markers within the tumour microenvironment, an avenue we did not 
explore in this study, might prove more useful in predicting patient outcome.  
 
Potential limitations of the present study were its retrospective design and inclusion of a small 
number of patients (n=32) from a single institution. Due to the study design, analysis was subject to 
biases in data recording and collection that inherently result from investigations of a retrospective 
nature. It is possible only significant or noticeable events were reported by patients or clinicians, 
leaving less serious or unnoticed events unaccounted for. Despite these potential drawbacks, a high 
incidence of low-grade irAEs affecting a wide range of organs were observed in the current study, 
demonstrating thorough event recording by managing physicians. The collection of data from a 
single institution may in fact be advantageous, capturing a holistic view of anti-PD-1 treated 
patients and a greater likelihood of consistent reporting of clinical events and their management. 
Additionally, due to the recent approval of the first anti-PD-1 agents, nivolumab and 
pembrolizumab in 2014, these agents represent a new area of research.75,76 Besides large regulatory 
clinical trials, many studies to date have been conducted for exploratory purposes and involve 
samples sizes similar to that of the current study.177,179,180  For example, a recently published study 
by Sanmamed et al, (2017) analysed serum IL-8 levels in 29 melanoma patients treated with 
nivolumab or pembrolizumab.177  
 
In summary, this chapter assessed the potentiality of clinicopathological variables as biomarkers of 
patient outcome to ICI-therapy. We did not identify any statistically significant associations 
between clinicopathological variables and patient outcome, due to a relatively small sample 
number. Thus, no candidate markers of a clinicopathological origin were identified to potentially 
predict patient outcome with regard to survival, response or the development of toxicity. Despite 
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this, results of this chapter suggest that patients ineligible for early clinical trials of immune 
checkpoint inhibitors may be effectively treated in general practice with nivolumab or 
pembrolizumab, but perhaps carry a greater risk of developing toxicity. Further research in a larger 



































3! Analysis of Drug Concentration and Anti-Drug Antibodies 
3.1! Introduction 
As with all therapeutic antibodies, pembrolizumab and nivolumab can potentially produce 
undesirable immunogenic responses upon administration, leading to the production of anti-drug 
antibodies.136,137 More importantly, however, these anti-drug antibodies have been associated with 
decreased efficacy and/or increased toxicity for a range of therapeutic mAbs.140,142,144,152 Based on 
this association, we questioned whether anti-drug antibodies are generated in patients undergoing 
ICI-therapy. If so, their production may predict how patients respond to treatment and assist in 
guiding therapeutic regimens. Thus far, limited studies have examined the prevalence of anti-drug 
antibodies in patients receiving immune checkpoint inhibitors and even fewer have investigated 
their association with patient outcome. The largest studies, conducted as part of the regulatory 
approval of these drugs, use a conventional bridging ELISA technique that has considerable 
limitations with respect to the detection of ADAs (see section 1.4.2 in Chapter 1).148  
To address this limitation, the Haematology research group (HRG) based at the University 
of Otago (Christchurch, NZ), developed a modified ELISA for the analysis of drug and anti-drug 
levels. Last year, they published a study describing the use of this method in patients with 
rheumatoid arthritis and inflammatory bowel disease receiving anti-TNF mAbs.178 The ELISA 
developed by the HRG follows similar principles to the affinity capture elute (ACE) assay described 
by Bourdage et al, (2007). In that assay, the patient serum undergoes an initial acidification step in 
order to break up any existing drug-ADA complexes and then captures all ADA present.141 The 
ELISA method used in the current study is analogous to the ELISA developed by the HRG. 
However, instead of applying the assay to patients receiving mAbs for autoimmune disease, it has 
been applied to patients receiving anti-PD-1 mAbs (nivolumab or pembrolizumab) for the treatment 
of metastatic melanoma.  
The specific aim of this chapter was to examine whether the production of anti-drug 
antibodies in patients undergoing ICI-therapy alters patient outcome. If so, detection of anti-drug 
antibodies may act as a predictive biomarker during ICI-therapy, allowing physicians to guide and 
manage treatment more effectively in general practice. Based on previous studies of therapeutic 
mAbs, we hypothesized patients who produce anti-drug antibodies exhibit decreased efficacy of 
treatment and/or an increased risk of toxicity. Additionally, we hypothesized that patients who 
produce ADAs have a lower circulating drug concentration. To investigate this, an in-house 
developed ELISA was used for analysis of drug concentrations and anti-drug antibody levels in sera 
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from patients undergoing immune checkpoint therapy. Resulting data was analysed for associations 
with patient outcome, including the development of immune-related toxicities, response and 
survival. To our knowledge, this study is the first to test these parameters in patients undergoing 
ICI-therapy using an acid dissociation ELISA method.  
 
3.2! Materials and Methods 
3.2.1! Study Participants 
This study involved patients treated for stage III or IV metastatic melanoma with nivolumab or 
pembrolizumab by Canterbury Regional Cancer and Haematology services. Patients were eligible 
for inclusion if they had a confirmed diagnosis of stage III or IV metastatic melanoma and received 
at least one dose of nivolumab or pembrolizumab at Christchurch Hospital, New Zealand. 
Treatment was administered according to national PHARMAC guidelines, as described in chapter 
2, section 2.2.2. Patients under 18 years of age or with a haemoglobin level lower than 90 g/L were 
excluded from blood sample analysis. Patients unable to provide informed consent or participating 
in a competing clinical trial were also excluded. Ethical approval for this study was obtained from 
the Southern Health and Disability Ethics Committee of New Zealand (approval 16/NTB/139) and 
all participants gave written informed consent for use of biomaterials and available 
clinicopathological data for scientific purposes. Patient age, gender, response to treatment, 
appearance of irAEs was collected from electronic medical records and clinician notes. Collection 
of data was completed after appropriate training and all information was collected and collated 
under the supervision of Dr. Matthew Strother.  
 
3.2.2! Patient Samples 
Serum samples were collected from patients after informed consent and approval from the Southern 
Health and Disability Ethics Committee (New Zealand). Sera from patients receiving nivolumab or 
pembrolizumab monotherapy for metastatic melanoma (stage III or IV) was collected at trough time 
points, immediately prior to the patients next scheduled infusion, as shown in Figure 3.1. Samples 
were collected from patients at multiple infusion points throughout treatment. Collection of samples 
from infusion 1 was not mandatory but, following initiation of sample collection, sera was collected 
at consecutive infusion time points. Drug naïve control sera were obtained from a panel of stored 
diagnostic Immunology laboratory samples that had undergone testing for tissue transglutaminase 
IgA. Serum samples were stored at -80. 20µl aliquots were separated and stored at -20 until 
use. Samples were assayed for therapeutic antibody concentration and levels of anti-ICI antibodies. 





Figure 3.1: Procedure of anti-PD-1 therapy and collection of blood samples in this study. After 
assessment of patient eligibility and consent, blood samples were collected from patients 
immediately before infusion of an anti-PD-1 agent (Q3W). At 12 weeks, a CT scan was performed 
to assess response (according to RECIST criteria). Complete response, partial response or stable 
disease allowed the patient to initiate a new cycle of anti-PD-1 treatment, whereas progressive 
disease led to cessation of treatment. No further blood samples were collected from patients who 
stopped therapy. 
 
3.2.3! Reagents and Equipment 
Wash buffer consisted of 0.1% tween in PBS and washing was completed using WellwashTM 
microplate washer (Thermo ScientificTM). Nivolumab (Opdivo®), Pembrolizumab (Keytruda®), 
Adalimumab (Humira®) was obtained from the residual contents of vials that had been used for 
patient infusions. All samples and standards were diluted in 1% milk powder (MP) in PBS. 1% MP 
was prepared by diluting 5% non-fat dried milk powder (Anchor) (stored at 4°C in PBS and azide) 
in PBS. Goat Anti-human IgG (Fc specific-F(ab’)2) was obtained from Sigma and stored at 
500µg/ml with H2O. Recombinant human TNFα (E.coli derived, carrier protein free, R&D systems) 
was stored at 10µg/ml in PBS. Recombinant human His-tagged PD-1 was obtained from R&D 
systems, and Streptavidin-HRP (0.83g/L) from Dako. All reagents were stored at 4°C, unless noted 
otherwise. Optical density was measured using a MultiskanTM GO microplate spectrophotometer 




3.2.4! Biotin-therapeutic antibody conjugates 
Pembrolizumab was biotinylated using EZ-Link NHS-PEG4-Biotinylation Kits (Pierce, 21455), 
according to manufacturer’s instructions. In brief, 170µl of water was added to the NHS-PEG4-
Biotin and transferred to the therapeutic antibody solution, containing 2mg/ml of pembrolizumab in 
PBS. After incubation (30 minutes, room temperature), non-reacted NHS-PEG4-Biotin was 
removed using a desalting column. After dialysis, biotinylated-therapeutic antibody was stored at 
4. Nivolumab was biotinylated using the same method described above by Dr. Barry Hock 
(Haematology Research Group, University of Otago, Christchurch, NZ). The specificity and 
optimal dilution of biotinylated antibodies was analysed using a capture ELISA. Plates were coated 
with TNF, PD-1, Goat anti-human IgG (positive control) or PBS (negative control) and 
supplemented with either nivolumab (2µg/ml-0.25µg/ml), pembrolizumab (2µg/ml-0.25µg/ml), 
adalimumab (1µg/ml) or no drug (1% MP in PBS).  
 
3.2.5! Capture ELISA for Analysis of Drug Concentrations 
Enzyme-linked immunosorbent assay (ELISA) for analysis of nivolumab and pembrolizumab 
concentrations were performed in 96 well microtiter plates (Nunc-Maxisorp) precoated (o/n, 4°C) 
with 100µL/well PD-1 at 500ng/mL in PBS. Plates were washed (Tween 20/PBS x3) and blocked 
with 1% milk powder for 30 minutes at 37°C. Following removal of blocker, samples (100µg/well) 
were added and plates incubated (2 hours, 37°C). Following washing plates were incubated with 
100µg/well Goat anti-human IgG biotin (Fc specific-F(ab’)2, Sigma) diluted 1 in 1000 in 1% MP 
supplemented with 2% goat serum. After incubation (1 hour, 37°C) and subsequent washing, wells 
were incubated (30 minutes, 37) with 100µl/well streptavidin-HRP (Sigma) diluted 1 in 7000 in 
0.1% bovine serum albumin/PBS. Wells were washed and developed using 3,3’,5,5’-
Tetramethylbenzidine (TMB) substrate (5 minutes, room temperature). The reaction was stopped by 
acidification (2.5 mmol H2S04) and optical density was read at 450nm. The key steps of this method 




Figure 3.2: Key steps of the capture ELISA method used for analysis of anti-PD-1 drug 
concentrations. (1) An ELISA plate is coated with PD-1. (2) Patient serum is added to a PD-1 
coated ELISA plate and anti-PD-1 therapeutic antibodies (nivolumab or pembrolizumab) bind to 
PD-1. (3) Biotinylated goat anti-human IgG is added and binds to the anti-PD-1 agent. (4) SA 
conjugated to HRP binds to biotin and reacts with TMB to form a detectable coloured product.  
 
3.2.6! Calibration Curves 
Calibration curves for the estimation of drug concentrations were prepared from known stock 
concentrations of nivolumab and pembrolizumab by serial dilution in 1% MP plus 2% goat serum. 
Samples of known concentrations were analysed by capture ELISA following the same method 
described above (section 3.2.5). Previous experiments conducted by the HRG indicated a range of 
dilutions suitable for the generation of calibration curves in the current study. Initially, nivolumab 
and pembrolizumab calibrators were used in the range of 200-0.8ng/ml and 100-0.4ng/ml, 
respectively. However, the concentration of calibrators was too high and large error bars were 
produced questioning the accuracy of the curve. To optimize the standard curve, a second capture 
ELISA was conducted. In the second approach, optimized calibration curves were produced using 
nivolumab and pembrolizumab calibrators ranging from 50-0.2ng/ml. Serum drug concentrations 
were interpolated from the optimized calibration curve that was obtained using a 4-parameter 
logistic curve fitting program (GraphPad Prism version 6.0).  
 
3.2.7! Standard Bridging ELISA for Detection of ADA  
A bridging ELISA for detection of anti-drug antibodies was performed in a flat-bottom 96 well 
microtiter plate (Maxisorp). Key steps of the bridging ELISA method used in this study are shown 
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in Figure 3.3A. The plate was coated with nivolumab or pembrolizumab at a concentration of 
5µg/ml in PBS by adding 100µl per well. Following incubation (2 hours, 37°C), the plate was 
washed and blocked for 30 minutes (37°C) with 1% milk powder (1% nonfat milk powder [98% fat 
free, Anchor] in PBS). 100µl of sample, diluted 1 in 50 in 1% MP, was added to the wells and 
incubated (1.5 hours, 37°C). The plate was washed and 100µl of biotinylated therapeutic antibody 
(diluted 1 in 1000 in 1% MP supplemented with 1% Goat serum) was added. Following incubation, 
(1 hour, 37°C), the plate was washed and wells were incubated with 100µl SA-HRP diluted 1:7,000 
in 0.1% BSA/PBS before washing and development (5 minutes, room temperature) with TMB 
substrate. The reaction was stopped by acidification (2.5mmol H2S04) and the optical density was 
read at 450nm.   
 
3.2.8! ACE assay (Modified Bridging ELISA) for Detection of ADA  
ELISA for detection of anti-drug antibodies were performed in flat-bottom 96 well microtiter plates 
(Maxisorp). Key steps of the ACE ELISA used in this study are shown in Figure 3.3B. Plates were 
coated with nivolumab or pembrolizumab at a concentration of 5µg/ml in PBS by adding 100µl per 
well. Following incubation (2 hours, 37°C), plates were washed and incubated for 30 minutes 
(37°C) in 200µl wash buffer. In fresh 96 well V bottom microtiter plates (Maxisorp), aliquoted 
samples (15µl) were acidified with 100µl acetic acid (300mM) to dissociate ADA-free drug 
complexes. Following incubation (40mins, 37°C) 100µl neutralizing buffer (Tris 0.5M, pH 
9.5/0.2% Tween 20) was added to the samples. Neutralised samples (100µl) were then transferred 
to the drug-coated plates and incubated overnight (4°C) to allow ADA the opportunity to bind solid-
phase drug. The following day, plates were washed once in 0.1% Tween and twice with water. 
Bound ADA was then eluted by addition of 65µl 300mM acetic acid for 10 minutes at room 
temperature. Fresh 96 well microtiter plates were loaded with 50µl of Tris buffer (1M, pH 9.5). 
50µl of the acid eluate was transferred to the Tris buffered plates and incubated for 1.5 hours at 
37°C to allow binding of eluted ADA to the wells. Following washing (0.1% Tween), plates were 
blocked with 1% milk powder (1% nonfat milk powder [98% fat free, Anchor] in PBS) for 30 
minutes at 37°Cµl of biotinylated therapeutic antibody (diluted 1 in 1000 in 1% MP 
supplemented with 1% Goat serum) was added and incubated (1 hour, 37°C). Plates were washed 
before SA-HRP incubation and colour development as described above for the detection of ADA 
using a bridging ELISA. The greater the amount of captured anti-drug antibodies in a sample, the 
more TMB substrate formed and subsequently, the higher the optical density of the sample. Mean 
optical density of samples was expressed as a percentage change, relative to the overall mean 
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optical density measured in all drug naïve (control) patient sera. We classified positive samples, as 





Figure 3.3: Key steps of the Bridging ELISA (A) ACE ELISA (B) used for detection of anti-
drug antibodies in this study. (A) ADAs from patient serum bind to anti-PD-1 antibody (drug) 
coated on an ELISA plate. These ADAs are subsequently detected with anti-PD-1 antibody (drug) 
labelled with biotin. Biotinylation allows for detection of the anti-PD-1 antibody and attached ADA 
with an enzyme and measurable substrate. (B) Firstly, acidification of patient serum dissociates 
ADA-drug complexes into free anti-PD-1 antibody and free ADA. Following neutralization, ADAs 
are affinity captured in the in the presence of solid-phase drug. After the removal of free drug by 
washing, acid-eluted ADA is transferred onto a fresh ELISA plate. Captured ADAs can then be 






3.2.9! Statistical analysis 
All analyses were carried out using Microsoft Excel version 15.38 and GraphPad Prism version 6.0 
(San Diego, CA, USA). Values were expressed as mean ± standard error of the mean. 
 
3.3! Results 
3.3.1! Patient Population 
A total of 23 trough serum samples from 8 patients undergoing immune checkpoint inhibitor 
therapy were analysed in this study. Of these patients, 6 (75%) were treated with pembrolizumab 
and 2 (25%) with nivolumab monotherapy. 16 samples were obtained from pembrolizumab-treated 
patients, whilst the remaining 7 samples were collected from patients receiving nivolumab. Trough 
samples from patients varied in start time collection point, ranging from prior to infusion 1 to prior 
to infusion 24. The maximum number of consecutive samples collected from one patient throughout 
treatment was four. Characteristics of patients included in analysis, undergoing ICI-therapy, are 
shown in Table 3.1. An additional 23 samples from drug-naïve diagnostic laboratory samples were 










Table 3.1: Clinical Characteristics and responses of ICI-treated patients analysed in this study 
Patient Anti-PD-1 agent Age Gender Best Overall 
Response 
irAEs No. of samples 
provided 
Cycle of first 
sample collection 
1 Pembrolizumab 59 m PR Cough, fatigue, dyspnea, arthralgia, 
pneumonitis, hypersensitivity reaction, 
rash 
4 3 
2 Nivolumab 63 f PR Cough, fatigue, dyspnea, diarrhea, 
hypoadrenalism, decreased appetite 
2 21 
3 Pembrolizumab 68 m PR Rash, constipation, diarrhea, 
hypothyroidism, fatigue 
4 8 
4 Nivolumab 77 f PR Fatigue, lymphopenia 5 24 
5a Pembrolizumab - f - - 3 11 
6 Pembrolizumab 56 f PR Nausea, fatigue 3 9 
7 Pembrolizumab 57 f Not yet 
evaluated 
Hypersensitivity reaction 1 3 
8b Pembrolizumab - m - - 1 1 
a,b Missing data   
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3.3.2! Analysis of reagent specificity  
Prior to analysis of patient serum samples, assays were performed to confirm the specificity of 
reagents utilized in the drug and ADA ELISAs. Biotinylated anti-PD-1 antibodies had been prepared 
in the laboratory as described in section 3.2.4 and were analysed to confirm their specificity and the 
optimal dilution for their use. Biotinylated nivolumab and pembrolizumab strongly bound PD-1 but 
did not react with a control recombinant protein, TNF. In contrast, the anti-TNF antibody adalimumab 
did not react with PD-1 but strongly bound TNF. Results of this capture ELISA are displayed in 
Figure 3.4.  
 
 
Figure 3.4: Binding specificity of nivolumab and pembrolizumab. The specificity and optimal 
dilution of biotinylated anti-PD-1 antibodies was analysed using a capture ELISA. Plates were 
coated with TNF (positive control), PD-1 or PBS (negative control) and supplemented with either 
nivolumab, pembrolizumab, adalimumab or no drug. Biotinylated anti-PD-1 agents bound PD-1 
and adalimumab bound TNF. Data is expressed as mean ± SEM.  
 
3.3.3! Analysis of Patient Drug Concentrations 
Following optimization of the calibration curve (Figure 3.5 and Figure 3.6), a capture ELISA was 
used to analyse drug concentrations in patient samples. Initially, investigation of drug concentrations 
was completed in a subset of patient samples, specifically in three patients treated with 
pembrolizumab (patient 1, 5 and 6) and two patients treated with nivolumab (patient 2 and 4), to 




























were diluted 1 in 1000 in 1% MP. However, mean optical densities from 4 of the 5 patients analysed 
were outside the range of the standard curve and thus, the drug concentration in these samples was 
not able to be quantified. As the patient samples were above the range of the standard curve, a 
subsequent ELISA was completed on samples from patients 2,4,5 and 6 ranging in dilutions from 1 
in 1000 to 1 in 16,000. Drug concentrations from samples diluted 1 in 8000 and 1 in 16,000 were able 
to be interpolated from the calibration curves. However, a 1 in 8000 dilution was deemed a suitable 
dilution for subsequent analysis of drug concentration in patient samples. Values from samples of this 
dilution fell within the linear part of the calibration curve permitting greater accuracy of drug 
concentrations in further analysis.  
 Due to time constraints and a low number of nivolumab-treated patients available for analysis, 
no further analysis was completed on samples from patients 2 and 4. Instead, a capture ELISA was 
used to analyse drug concentrations of all samples belonging to the 6 pembrolizumab-treated patients. 
The results of this ELISA are shown in Figure 3.7 and Figure 3.8. The mean trough concentration of 
pembrolizumab in this patient subset was 17.6µg/ml, ranging from 0.79 to 86.7µg/ml. Patient 1 had 
the lowest levels of pembrolizumab and was the only patient to display concentrations lower than 
1µg/ml. Specifically, patient 1 had pembrolizumab levels of 0.83, 0.79, 0.80 and 1.07µg/ml prior to 
treatment cycles 3, 4, 5 and 6, respectively. Patient 8 had a similarly low level of pembrolizumab 
(1.47µg/ml). The maximum trough level of pembrolizumab was observed in patient 5 who had a 
concentration of 86.7µg/ml prior to cycle 11 of treatment. The concentration of pembrolizumab in 
patient 5 decreased to 24.7 and 20.6µg/ml in subsequent treatment cycles. In contrast, the trough 
concentration of pembrolizumab in patient 6 increased throughout treatment from 14.8µg/ml prior to 
cycle 9 to 30.7µg/ml prior to cycle 10. The same trend occurred in patient 3, who exhibited slightly 
increased levels throughout treatment from 15.9µg/ml prior to cycle 8 and 9 to 18.07 and 18µg/ml 
prior to cycle 10 and 11, respectively. The only available sample from patient 7 had a level of 
12.12µg/ml of pembrolizumab. Analysis of samples from drug naïve (control) patients generated low 





Figure 3.5: Initial calibration curves of anti-PD-1 agents. Calibration curves were prepared with 
a capture ELISA using nivolumab (A) and pembrolizumab (B) calibrators ranging from 200-




Figure 3.6: Optimised calibration curves of anti-PD-1 agents. Calibration curves for analysis of 
drug concentrations were prepared with a capture ELISA using nivolumab (A) and pembrolizumab 
(B) calibrators ranging from 50-0.2ng/ml. Data is represented as mean ± SEM. 
 
 





























































Figure 3.7: Circulating pembrolizumab concentration in patients. The concentration of drug in 
samples from pembrolizumab-treated patients (n=6) and drug naïve individuals (n=18) were 
analysed using a capture ELISA. Resulting optical densities were used to determine pembrolizumab 
concentration from the calibration curve. Markers represent the mean pembrolizumab concentration 













Figure 3.8: Circulating concentration of pembrolizumab in patients throughout treatment. A 
capture ELISA was used to determine the concentration of pembrolizumab in four patients who 
provided multiple samples throughout treatment. Time point 1 corresponds to the time at which the 
patient provided their first sample, before collection of their second (time point 2), third (time point 
3) and fourth (time point 4) samples at three-weekly intervals. Markers represent the mean 









































3.3.4! Detection of ADAs in Patient Serum using an ACE ELISA 
The in-house developed ACE assay (modified bridging ELISA) was used to measure levels of anti-
pembrolizumab antibodies in 6 patients undergoing pembrolizumab monotherapy. The results of this 
assay are displayed in Figure 3.9. Four samples displayed a higher mean optical density than all 
samples tested. These four samples, belonging to patient 1, had a 90, 81, 63 and 43% increase in 
optical density compared to control samples. Samples belonging to the remaining 5 pembrolizumab-
treated patients ranged in percentage change of mean optical density from -4% to 18%.  
 
            
Figure 3.9: Anti-drug antibody levels in patient samples. An ACE-ELISA was used to detect 
ADAs in 16 samples from 6 pembrolizumab-treated patients. ADAs were detected in four samples 
from one patient (patient 1). The mean optical density of samples was expressed as a percentage 
change, relative to the overall mean optical density measured in all drug naïve (control) patient sera.  
 
3.3.5! Analysis of ADA in Patient Serum using a Standard Bridging ELISA 
To investigate concordance between ACE and bridging ELISA-based methods, sera from patients 
previously analysed using the ACE ELISA were subjected to analysis with a standard bridging ELISA 
method, as described in section 3.2.7. Serum from a patient positive for ADAs using the ACE assay 
(patient 1) and from a patient negative for ADAs using the ACE assay (patient 5) were analysed using 
the bridging ELISA. Although patient 1 and patient 5 were pembrolizumab-treated, a section of wells 
was coated with nivolumab, rather than pembrolizumab to act as a negative control. Further controls 
included the analysis of samples containing serum from two drug-naïve patients (negative control), 
goat serum (negative control) or goat anti-human IgG (positive control).  
Results of analysis using the bridging ELISA are shown in Figure 3.10. No anti-drug 
antibodies were detected in patient 1 or patient 5. The mean optical densities of pembrolizumab-




























respectively. Similarly, pembrolizumab-coated wells of drug-naïve patient serum displayed mean 
optical densities of 0.082 (control patient A) and 0.084 (control patient B). The mean optical density 
of these samples in nivolumab-coated wells was 0.073 (patient 1), 0.073 (patient 5), 0.072 (control 
patient A) and 0.073 (control patient B). No antibodies were detected in the sample containing goat 
serum, showing mean optical densities of 0.084 in pembrolizumab-coated wells and 0.073 in 
nivolumab-coated wells. In contrast, antibodies were detected in the sample containing goat-anti 
human IgG. In pembrolizumab and nivolumab-coated wells containing goat-anti human IgG, the 




Figure 3.10: Levels of ADAs in samples analysed with bridging ELISA. Selected patient 
samples and controls were analysed for ADAs using a standard bridging ELISA. No ADAs were 
detected in patient samples. GS, Goat serum; G!H, Goat anti-human antibody. Data is represented 
as mean ± SEM. 
 
3.3.6! Relationship between ADA, Drug Levels and Patient Response   
The prevalence of anti-pembrolizumab antibodies (ADAs) in patient 1 was accompanied by low 
trough levels of pembrolizumab compared to other patients, as shown in Figure 3.11. Four 
consecutive trough samples, commencing prior to infusion number 3, were available for analysis 
from patient 1. According to a reduction in mean optical density, the level of ADAs in patient 1 
decreased throughout treatment (Figure 3.11). The mean optical density reduced from 1.16 prior to 
infusion three to 0.154 prior to infusion 6. The mean optical densities from trough samples taken 






















pembrolizumab antibodies. Although the presence of anti-pembrolizumab antibodies was associated 
with lower drug levels in this patient (range 0.79-1.07µg/ml), the reduction of ADAs throughout 
treatment was not associated with a significant increase in pembrolizumab trough levels, which 
stayed relatively constant throughout treatment, only increasing by 0.24µg/ml (Figure 3.11). At the 
time of analysis, patient 1 had exhibited a partial response to treatment as indicated by an initial 
restaging CT scan and according to RECIST criteria. However, throughout treatment, patient 1 
experienced a range of toxicities including fatigue, cough, dyspnea, arthralgia, pneumonitis and 





Figure 3.11: Drug concentrations and anti-drug antibody levels in Patient 1 throughout 
treatment. Four samples from patient 1, collected at infusion 3 and three subsequent infusions, 
were analysed using a capture ELISA and ACE-ELISA for circulating pembrolizumab 
concentrations and ADAs, respectively. Anti-drug antibody levels are represented as mean ± SEM 
and drug concentration markers represent the mean pembrolizumab concentration of individual 
samples analysed in duplicate. 
 
3.4! Discussion 
Equivalent to other therapeutic antibodies, the administration of ICI antibodies has the potential to 
elicit undesirable immunogenicity, leading to downstream consequences on patient 
outcome.136,137,158 Of particular relevance, are clinical reports of decreased efficacy and/or increased 
toxicity occurring within patients treated with mAbs.140,142,144,152 Increasing evidence suggests 
monitoring of therapeutic antibody levels and their respective ADAs can help guide treatment 
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decisions and improve the clinical outcomes of patients.173, 174 However, current detection methods 
possess a range of limitations, restricting their routine use in general practice.146 Thus, this chapter 
incorporated an in-house developed ELISA in the measurement of drug and anti-drug antibody 
levels of patients undergoing ICI-therapy and analysed their association with patient outcome. 
 
Initially, this chapter explored circulating drug concentrations of patients treated with anti-PD-1 
agents. The mean pembrolizumab trough concentration of samples from patients in our study 
(17.6µg/ml) was slightly lower than in previous studies, which have estimated a mean trough 
concentration of 23.5µg/ml.148 An explanation for this slightly lower mean concentration may relate 
to the proportion of samples in this study belonging to patient 1 (4 out of 16, 25%). All four 
samples from patient 1 had low pembrolizumab concentrations of less than 1.5µg/ml and coincided 
with the detection of anti-drug antibodies, which is to be discussed in subsequent paragraphs. 
Besides patient 1, patient 5 (86.7µg/ml) and patient 8 (1.47µg/ml) also had pembrolizumab 
concentrations outside the range expected from published data.148,175 These outliers may be due to 
flaws in experimental technique or inter-individual variations in pharmacokinetic parameters, 
resulting in different circulating drug concentration-time profiles after administration of similar 
doses to different patients.175  
 
The cycle at which samples were collected from patients may be a contributing factor to the wide 
range of pembrolizumab-concentrations observed in this study (0.79-86.7µg/ml). Although, all 
serum samples from pembrolizumab-patients were collected at trough level, the samples were 
collected from patients during different cycles of treatment (as they came through the clinic during 
this study). With repeated administration, the concentration of drug is expected to gradually 
increase until it reaches a steady state, as shown in Figure 3.12.175 Thus, patients further along in 
their treatment regime are expected to have higher drug levels than patients at the beginning of 
treatment. This is exemplified in this study by patients 5 and 6, who not only had the highest 
circulating concentration of pembrolizumab, but also had received the greatest number of 





Figure 3.12: Predicted pembrolizumab concentration-time profiles during multiple dosing 
with the regimens included in clinical trials for melanoma and NSCLC. Reprinted from 
Ahamadi et al (2017).175 
 
Previous immunogenicity analyses have estimated a low prevalence of anti-drug antibodies in 
patients undergoing ICI-therapy.148,182  In an assessment report, conducted by the European 
medicines agency, anti-drug antibodies were detected in 1.1% (29 out of 2,632) of patients treated 
with pembrolizumab.148 In contrast, our study indicated a higher prevalence of anti-drug antibodies 
in pembrolizumab-treated patients. Of the 6 pembrolizumab-treated patients analysed in our study, 
ADAs were detected in 1 patient (17%). There are several possible explanations for the higher 
prevalence observed in our study. Obviously, caution needs to be exercised when interpreting data 
from a small explorative study such as this and one explanation is that our data may be due to 
chance. However, it is interesting to note that when analysis was completed using a conventional 
bridging ELISA, no anti-drug antibodies were detected in any of the 6 pembrolizumab-treated 
patients. Therefore, a probable explanation for contrasting results, not only within our study but 
with previous literature, is the use of different methods to detect ADAs. A key problem with 
bridging ELISAs is the inability to detect ADAs in the presence of drug and monovalent IgG4 
ADAs, limitations we sought to overcome in this study through the use of a modified ACE-
ELISA.146,158 As with many other immunogenicity studies, the assessment report described above, 
analysed samples using a standard bridging ELISA. In our study, ADAs were analysed using both a 
bridging ELISA and modified ACE ELISA, but were only detected when using the latter method. 
Our data suggests that bridging ELISAs can produce false-negative results and may therefore, 
inaccurately estimate the prevalence of anti-drug antibodies in patients treated with pembrolizumab. 
More importantly, the extent to which anti-drug antibodies negatively influence patient outcome 




To confirm the patient positive for ADAs (patient 1) in our study was a true positive, samples from 
this patient could be subjected to further analysis using techniques with known high sensitivity and 
specificity. For example, the homogenous mobility shift assay, which displays higher sensitivity 
and specificity than ELISA methods, could be applied. An intended future purpose of the current 
work is the translation of methodology into a clinical setting. The HMSA requires specialist 
equipment and laboratory personnel, restricting its use in routine mAb monitoring and thus, was not 
initially applied to samples in this study.146 
 
Based on previous literature regarding therapeutic monoclonal antibodies, we hypothesized that 
patients who produce anti-drug antibodies exhibit (1) a decreased efficacy of treatment and/or (2) an 
increased risk of toxicity. We also hypothesized (3) that these patients would have lower levels of 
circulating drug. Part 1 of our hypothesis was not supported by results of the current study. The sole 
patient who was identified as producing anti-pembrolizumab antibodies (patient 1), exhibited a 
partial response to treatment. This response may have been explained by the presence of an 
effective concentration of pembrolizumab circulating within the patient. Surprisingly, however, all 
four samples belonging to patient 1 contained low drug concentrations, conflicting our third 
hypothesis, and patient 1 was the only patient analysed to have drug levels less than 1µg/ml. A 
possible explanation for the partial response of patient 1 to treatment is that a minimum effective 
concentration of pembrolizumab was present prior to collection of trough blood samples. In the 
days following infusion of pembrolizumab, drug levels may have been high enough to induce a 
therapeutic effect and produce a partial response in patient 1.  
 
However, analysis of drug and anti-drug antibody levels is not usually performed at peak time 
points due to the inability of ELISAs to accurately detect anti-drug antibodies in the presence of 
high levels of drug.146 As to why low drug levels were detected in trough samples remains to be 
determined, but may be attributed to the ability of anti-drug antibodies to increase clearance of 
mAbs. The binding of anti-pembrolizumab antibodies to pembrolizumab to form large immune 
complex may trigger endogenous elimination processes, promoting clearance of the drug.158 The 
subsequent clearance of the drug (complexed with ADA) may explain the low drug levels present in 
patient 1 and their inability to accumulate higher levels of drug even with repeated infusions. This is 
supported by a small increase of pembrolizumab levels in patient 1 throughout treatment, in 
conjunction with declining levels of ADAs. However, the small increase observed throughout 
treatment (0.24µg/ml) is unlikely to be of clinical relevance. It would be interesting to examine the 
levels of drug and anti-drug antibodies of patient 1 in subsequent treatment cycles to examine 
whether drug levels of this patient continued increasing to clinically relevant levels. It should be 
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noted that serum samples analysed from patient 1 were collected from infusions 3. Although these 
infusion time points corresponded with a partial response to treatment, this patient may have had 
clinically relevant levels of pembrolizumab high enough to produce a response, prior to collection 
of their first sample. This is not outside the realms of possibility as exemplified by patient 5, who 
experienced a significant decrease in pembrolizumab levels throughout treatment.   
 
An alternative explanation for the response to treatment observed in patient 1, is the speculation that 
anti-drug antibodies could elicit immune responses that are beneficial during ICI-therapy. In 
contrast to extensively studied mAbs used in autoimmune disease, the intention of ICI antibodies is 
to stimulate an immune response rather than suppress it.1,152 Specifically, anti-PD-1 agents 
primarily target T cells, enhancing their activation.1 Anti-drug antibodies have previously been 
reported to have a direct influence on T cells. The formation of immune complexes has been shown 
to bind Fc receptors on T cells, resulting in their co-stimulation.176 Additionally, the production of 
ADAs by B cells utilizes T cell dependent (and independent) pathways.158 Therefore, the immune 
response and activation of T cells caused by foreign sequences within anti-PD-1 agents, may be 
beneficial in forming a downstream response towards tumour cells. However, this idea is not 
supported by firm evidence and future work is required to uncover the underlying physiological 
mechanisms of ADAs within patients treated with ICIs before a causal relationship can be 
determined. Additionally, the majority of samples available for analysis in our study were from 
patients who experienced a partial response as their best overall response to treatment. To better 
characterize the negative influence of anti-drug antibodies on treatment efficacy and patient 
response, future work must involve the analysis of samples from patients who experienced disease 
progression.  
 
Conversely, part 2 of our hypothesis (i.e. patients who produce anti-drug antibodies exhibit an 
increased risk of toxicity) was supported in the present study. Patient 1 presented with a wide range 
of toxicities during ICI-therapy. Of particular note, is the onset of a hypersensitivity reaction. 
Infusion-related reactions have previously been linked to the production of anti-drug antibodies and 
may explain the hypersensitivity reaction observed in patient 1.140 These responses have been 
attributed to an inflammatory response towards the therapeutic mAb and therefore, an investigation 
of inflammatory markers in patients who produce ADAs is warranted. Outside the time constraints 
of this project, we aim to use a Proteome Profiler Human XL cytokine array kit (R&D systems) to 
measure relative levels of selected human cytokines and chemokines of patient 1. These markers 
could potentially predict the formation or downstream effects of anti-drug antibodies and immune 
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complexes, acting as a biomarker throughout treatment. Ultimately, the discovery and use of these 
markers could lead to improved clinical management and outcomes of patients treated with ICIs.  
It should be noted, however, that previous studies found not all patients who produce ADAs exhibit 
decreased efficacy and/or increased toxicity.140,144,145 Our study describes one patient case of anti-
drug antibody production and despite the associations described above, no conclusions can be 
drawn. Further investigations in a larger cohort of patients is required to determine the role of anti-
drug antibodies during ICI-therapy and their potential influence on patient outcome. In addition to a 
larger sample size, the collection of samples consistently throughout treatment would enable a 
better understanding of changes in drug and anti-drug antibody levels and their association with 
clinical events in individual patients.  
 
A drawback of this study is the inability of the in-house developed ELISA to detect anti-drug 
antibodies in high concentrations of drug. The analysis of samples collected at trough time point, 
when drug levels are at their minimum, reduces drug interference but re-association of anti-drug 
antibodies with free drug, rather than solid-phase drug on the ELISA plate, still remains a potential 
problem. Another potential limitation is the inability to detect non-neutralising anti-drug antibodies. 
Despite these drawbacks, the ACE-ELISA described in this study displays superior qualities over 
currently available assays, particularly in the context of routine therapeutic drug monitoring. It is a 
relatively simple and inexpensive method that can be performed using widely available reagents 
and laboratory equipment. Additionally, in contrast to alternative ELISA-based methods, the ACE-
ELISA allows detection of inhibitory ADAs complexed to drug. To our knowledge, no studies have 
yet been published incorporating the use of an acid-dissociation ELISA to detect anti-drug 
antibodies within patients undergoing ICI-therapy.  
 
In the present pilot study, an in-house developed ELISA was used to investigate drug and anti-drug 
antibody levels in patients undergoing immune checkpoint inhibitor therapy. The work described in 
this chapter demonstrates that commonly used bridging ELISAs may inaccurately detect the 
production of anti-ICI antibodies. Importantly, inaccuracies in detection may under-estimate the 
possible influence of ADAs on patient outcome. Our study describes the case of a patient who 
produced anti-pembrolizumab antibodies but, displayed both positive (partial response) and 
negative (toxicity) outcomes. However, due to a small study population, no conclusions can be 
drawn from the current study regarding the true prevalence of anti-ICI levels or their association 
with patient outcome. Whilst, the role of anti-drug antibodies is still yet to be determined, the 
preliminary data obtained from this study warrants further investigation. Future work investigating 
these parameters in a larger cohort is required to determine the prevalence and role of anti-drug 
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antibodies during ICI-therapy. Ultimately, future work could lead to the introduction of routine 
monitoring of ICIs and anti-ICI antibodies in general practice, with these parameters acting as 






































4.1! Summary of findings 
The recent success of immune checkpoint inhibitors has garnered attraction worldwide and led to a 
growing interest into research of these agents. However, the reasons why a subset of patients don’t 
respond to treatment or experience toxicity are poorly understood, a knowledge gap we sought to 
address in the current study. To prevent a proportion of patients exposed to an ineffective and 
potentially harmful therapy, this exploratory study aimed to investigate biomarkers that predict 
patient outcome during anti-PD-1 therapy. In this study, no clinicopathological markers were found 
to predict patient response, patient survival or the development of toxicity. In contrast to our 
hypothesis, patients at an increased risk of developing autoimmune diseases did not exhibit an 
increased risk in developing irAEs during ICI-therapy. However, our results demonstrated that 
patients typically excluded from clinical trials of anti-PD-1 agents could be effectively treated with 
immune checkpoint inhibitors, but perhaps carry a greater risk of toxicity.  
Furthermore, no immunogenic biomarkers were found to reliably predict outcome, due to the 
detection of anti-drug antibodies in one sole patient case. In agreement with our hypothesis, the 
patient who developed anti-drug antibodies experienced toxicities and had a lower level of 
circulating drug. In contrast, however, a partial response to treatment was observed in this patient, 
prompting the question as to whether ADAs influence the efficacy of ICI-therapy. Interestingly, we 
found contrasting results in detection of anti-ICI antibodies between a conventional bridging ELISA 
and an in-house developed acid-dissociation ELISA, suggesting bridging ELISAs may inaccurately 
detect the production of ADAs in patients treated with anti-PD-1 agents. Overall, the findings of 
this exploratory study add to current literature with regards to the use of anti-PD-1 agents in real-
life metastatic melanoma patients, but generate further questions surrounding the prevalence and 
role of anti-drug antibodies during ICI-therapy.  
 
4.2! Future directions 
The results in this study must be interpreted in the context of a small study population. Regardless, 
this study was intended as a preliminary exploratory analysis to identify possible biomarkers of 
patient outcome to ICI-therapy which, could then be validated with future work. Further research, 
recruiting patients from multiple locations, over a longer period of time, would enable acquisition of 
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a larger study population and the ability of significant conclusions to be drawn. Nonetheless, recent 
published studies investigating immune checkpoint inhibitors have employed smaller sample sizes 
than the current study and provided fundamental data, in which future work can build on. Likewise, 
this project provides preliminary data that warrants further investigation in a larger cohort and 
suggests several directions for future research.  
Firstly, outside the constraints of this project and in the immediate future, an investigation 
into inflammatory markers and patient outcome will be completed. An antibody array will be used 
to measure inflammatory markers from a patient of interest identified in this study. This patient of 
interest was one of the 32 patients reviewed in chapter 2 and was subsequently analysed for anti-
drug antibodies in chapter 3. Our data suggested this patient is of particular interest due to the 
production of anti-drug antibodies and the wide range of toxicities they developed throughout 
treatment. If the production and level of anti-drug antibodies does not directly predict patient 
outcome, downstream effectors might act as an indication of ADA formation and subsequently, 
function as a predictor of patient outcome. Based on the central role of ADA-drug immune 
complexes in the formation of toxicity and their ability to initiate downstream inflammatory 
pathways, a measurement of inflammatory cytokines and chemokines in this patient will help us, 
not only characterize the mechanisms of ADAs in patients undergoing ICI-therapy, but also shed 
light on the underlying physiological pathways mediating irAEs. It is hypothesized that the 
inflammatory profile of this particular individual will differ from, not only healthy individuals, but 
also from patients undergoing ICI-therapy who didn’t produce ADAs or experience similar 
toxicological consequences. Depending on the results of this array, individual inflammatory 
markers could then be pursued further to analyse their association with patient outcome. Samples 
from a larger group of patients could be subjected to analysis with an ELISA to identify potential 
biomarkers of patient response, survival or the development of toxicity.   
 Furthermore, the discrepancies in ADA detection between the in-house developed acid 
dissociation ELISA and a conventional ELISA described in chapter 3, indicate a need for further 
research. Firstly, with regards to the prevalence and role of anti-ICI antibodies and secondly, with 
regards to the methodology applied. To determine the role and prevalence of ADAs in patients 
undergoing ICI-therapy, a future analysis of samples from larger cohort of patients who experienced 
a range of responses including disease progression could be conducted. This would enable a more 
accurate representation of the prevalence of anti-ICIs in patients undergoing ICI-therapy and their 
association with response. Additionally, due to subtle differences in structure between anti-PD-1 
agents, future research could include patients treated with nivolumab monotherapy, as well as those 
undergoing pembrolizumab monotherapy. In our study, limited samples from nivolumab-treated 
patients were available for analysis. This is because, patients treated at Christchurch hospital are 
 
 69 
preferentially treated with pembrolizumab, which is administered is every three weeks, rather than 
nivolumab, which is administered every two weeks. Analysis of nivolumab, as well as 
pembrolizumab treated patients will enable a better characterization of, not only anti-PD-1 agents as 
a whole, but also individual therapeutic antibodies and their respective anti-drug antibodies.  
 It is clear from this study, that the in-house developed ACE-ELISA possesses superior 
qualities to that of the commonly used bridging ELISA. The ability of the ACE-ELISA described in 
chapter 3, to detect ADAs that were not detected by a conventional bridging ELISA method, 
warrants the further development of the method. Although we are not there yet, the routine 
monitoring of ICIs and anti-ICIs can only be introduced into general practice, given the availability 
of appropriate methodology. Future studies applying this method to various patient populations and 
subsequently, confirming positive (and negative) samples as true positives (or negatives) should be 
conducted. This will provide a better representation of the accuracy of this technique, with regards 




In this study, no clinicopathological or immunogenic biomarkers were found to reliably predict 
patient response, survival or the development of toxicity. However, two key observations were 
made. Firstly, patients excluded from initial clinical trials of anti-PD-1 agents may be effectively 
treated with ICIs and secondly, commonly used bridging ELISAs for detection of drug and anti-
drug parameters may inaccurately detect the production of anti-ICI antibodies. The observations 
from this study provide an insight into real-life metastatic melanoma patients treated with anti-PD-1 
monotherapy, and importantly, constitute a step towards the optimization of immune checkpoint 
inhibitors in clinical practice. If the potential role of anti-drug antibodies during ICI-therapy can be 
established, then monitoring of ADAs may be useful in guiding individual therapy, ultimately, 
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